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Zusammenfassung 
Sowohl verschiedene Kristalle als auch feste Nano- und Mikropartikel verursachen 
viele akute und chronische physiologische Störungen (Kristallopathien) wie Gicht, 
Pseudogicht, Atherosklerose, Silikose, Asbestose, Rhabdomyolyse, verschiedene Formen 
kristalliner Nephropathie, sowie Nephro-/Urolithiasis. Die meisten Kristall-induzierten 
Schädigungen gehen oft mit einer starken Entzündungsreaktion einher. Zusammen mit der 
Entzündung verursachen Kristalle auch Zelltod; die genauen molekularen Mechanismen der 
kristallinen Zelltoxizität sind aber bisher noch ungeklärt. Wir untersuchten den Kristall-
induzierten Zelltod von Neutrophilen Granulozyten. Dabei beobachteten wir das viele 
verschiedene Kristalle wie z.B. Calcium Oxalat (CaOx), Mononatrium-Urat (MSU), 
Calciumphosphat (CaP), Calciumpyrophsphat-Dihydrat (CPPD), Cystein, Cholesterol, Alaun, 
Asbest, Siliziumdioxid und Titan-Dioxid (TiO2)-Nanopartikel Neutrophil Extracellular Trap 
(NET) Formation und den damit verbundenen Zelltod der Neutrophilen, der NETose genannt 
wird, induzieren. Der genaue molekulare Mechanismus, der die NET-Formation verursacht, 
ist allerdings noch nicht bekannt.  
Nekrose wurde traditionell immer als nicht programmierter Zelltod angesehen, dem 
überhaupt keine biochemischen Mechanismen zugrunde liegen. Im Zusammenhang mit 
nekrotischem Zelltod wurden jedoch mittlerweile viele verschiedene biochemische 
Signalwege entdeckt die unter dem Begriff der regulierten Nekrose zusammengefasst sind. 
Deswegen gingen wir in unserer Hypothese davon aus dass NETose nur eine andere Art 
Zelltod mit bestimmten molekularen Mechansimen sein könnte. Wir fanden heraus dass 
MSU-Kristall-induzierter Zelltod von Neutrophilen die Signalkaskade der receptor-interacting 
protein kinase (RIPK) 1-RIPK3-MLKL vermittelten Nekroptose auslöst. Außerdem konnten 
wir zeigen, dass die RIPK-1-Stabilisatoren Necrostatin-1 oder Necrostatin-1s und der MLKL-
Inhibitor Necrosulfamid die NET-Formation von menschlichen und murinen Neutrophilen bei 
der MSU- oder PMA-induzierten Produktion von reaktiven Sauerstoffspezies (ROS) 
verhindern konnten. Diese Präparate haben jedoch keinen Einfluss auf die MSU- oder PMA- 
induzierte Produktion von reaktiven Sauerstoffspezies (ROS). Desweiteren konnte bei 
Neutrophilen von Patienten mit septischer Granulomatose (CGD) ein Mangel an PMA-
induzierter MLKL-Phosphorylierung gezeigt werden. Ferner verhinderte der genetisch 
bedingte Mangel von RIPK3 bei Mäusen die MSU-induzierte NET-Formation in vitro und in 
vivo. Folglich könnten bei der NET-Formation und dem Zelltod der Neutrophilen der ROS-
induzierte Signalweg der Nekroptose beteiligt sein. 
Zusammenfassung  v 
 
Außerdem beobachteten wir dass die Kristalle von CaOx, MSU, CPPD und Cystein in 
vitro bei verschiedenen Nicht-Immunzelltypen, wie z.B. murinen und humanen 
Tubulusepithelzellen, humanen Nieren-Progenitorzellen, murinen embryonalen Fibroblasten 
und humanen synovialen Fibroblasten, eine caspase-unabhängige Form des Zelltods 
verursachen, die aber durch den RIPK1-Stabilisator Necrostatin-1 inhibiert wurde. 
Zusammengefasst zeigen diese Daten, dass RIPK1, RIPK3 und MLKL neue therapeutische 
Ziele  bei der Therapie von Gicht und anderen Kristallopathien darstellen könnten. 
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Summary 
Various crystals as well as solid nano- and micro- particles cause injury in a wide 
range of acute and chronic physiological disorders (crystallopathies) including gout, 
pseudogout, atherosclerosis, silicosis, asbestosis, rhabdomyolysis, and diverse forms of 
crystalline nephropathy or nephro-/urolithiasis. Most of the crystal-induced injuries are 
associated with strong inflammatory responses. Together with inflammation, crystals also 
induce cell death; however the molecular mechanisms of crystal cytotoxicity remain elusive 
till date. We studied the crystal induced cell death in neutrophils. We observed that a wide 
range of crystals e.g. calcium oxalate (CaOx), monosodium urate (MSU), calcium phosphate 
(CaP), calcium pyrophosphate dihydrate (CPPD), cysteine, cholesterol, alum, asbestos, silica 
and titanium dioxide (TiO2) nanoparticles (20nm and 80nm) induce Neutrophil Extracellular 
Trap (NET) formation, and associated neutrophil cell death that is referred to as NETosis. 
However, the outside-in signaling pathway triggering NET formation is yet unknown.  
Traditionally, necrosis was always considered a non-programmed cell death, which 
does not involve any biochemical signaling mechanism. However, meanwhile many 
biochemical pathways have been discovered to be associated with necrotic cell death, known 
as regulated necrosis. Therefore, we hypothesized that NETosis might be just another form of 
cell death involving distinct molecular mechanism. We found that MSU crystal-induced 
neutrophil cell death triggers the signaling cascade of regulated necrosis pathway of receptor-
interacting protein kinase (RIPK) 1-RIPK3- MLKL mediated necroptosis. We show that the 
(RIPK)-1-stabilizers necrostatin-1 or necrostatin-1s and the MLKL-inhibitor 
necrosulfonamide prevent MSU- or PMA-induced NET formation in human and mouse 
neutrophils. These compounds do not affect MSU- or PMA-induced production of reactive 
oxygen species (ROS). Moreover, neutrophils of chronic granulomatous disease (CGD) 
patients are shown to lack PMA-induced MLKL phosphorylation. Further, genetic deficiency 
of RIPK3 in mice prevented MSU-induced NET formation in vitro and in vivo. Thus, NET 
formation and neutrophil death may involve the signaling pathway defining necroptosis 
downstream of ROS production.  
Furthermore, we found that crystals of CaOx, MSU, CPPD, and cystine trigger a 
caspase-independent cell death in vitro in different non-immune cell types e.g.  mouse and 
human tubular epithelial cells, human renal progenitor cells types, mouse embryonic 
fibroblasts (L929) as well as human synovial fibroblasts, which was inhibited by a RIPK1 
stabilizer necrostatin-1. Taken together, these data imply that RIPK1, RIPK3, and MLKL 
may represent novel molecular targets in gout or other crystallopathies.   
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1. Introduction 
1.1 Crystallopathies 
Crystals as well as crystal-like solid nano- and microparticles (for simplicity referred 
to as crystals) cause diverse acute and chronic medical disorders, which have not been 
considered a common disease entity (figure 1)
1
. These crystals interact with different cell 
types in the physiological setting, leading to specific pathophysiological mechanisms that lead 
to a disease condition. Crystals can form from intrinsic sources or enter the body from 
outside.  Crystallization inside the body mostly involves local supersaturation of minerals, 
dietary metabolites or drug overdose. Such crystal deposits often affect excretory organs such 
as the biliary and urinary tract where concentration and supersaturation is a common initiator 
of the crystallization process and stone formation (Table 1). Also, endogenous proteins can 
undergo self-assembly to polycrystalline structures. The process of beta-sheet fibrils self-
perpetuating fibrillation to plaque-like amyloid deposits in amyloidosis or Alzheimer disease 
resembles mineral crystallization around a nucleus. Particulate matter that enters the body 
from the outside mostly include occupational, environmental or cigarette smoking-related 
dust, mainly affect the lungs. Other sources of extrinsic particles are metallic, plastic or 
silicone implants, cosmetics or nanocarriers used for drugs. All of these can evoke similar 
responses as crystals. Particle size is a critical determinant of the tissue response. 
Macrophages and other phagocytes are usually the first to engulf particles for phagocytosis, 
which is possible for nanoparticles and microparticles of few micrometers in diameter. 
Phagosomes fuse with lysosomes that contain numerous lytic proteases. The inability of 
phagolysosomes to digest the nano- or microparticle cargo induces cell stress, autophagy, and 
eventually leakage of lysosomal content into the cytoplasm. Crystal needles and other larger 
particles that exceed the size of macrophages may induce giant cell formation as a way to 
internalize larger particles
2
. Calculi and implants of a much larger size are subjects of 
frustrated phagocytosis. Various crystal or crystal-like particle related diseases are listed in 
Table 1.  
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Table 1: Crystal- or crystal-like particulate-related diseases 
 
Crystal/particle Disorder Major disease manifestation 
 
 
Intrinsic inorganic crystals    
Brushite Nephro-/urolithiasis Renal colic  
Ca
++
 carbonate Cholecysto-/docholithiasis 
Nephro-/urolithiasis 
Biliary colic 
Renal colic 
 
Ca
++
 oxalate Nephro-/urolithiasis  
Acute oxalate nephropathy 
  Polyethelene glycol poisoning 
  Dietary oxalosis: Black tea, star  
     fruit, rhubarb, vitamin C, nuts, … 
  Bariatric surgery-/short bowl- 
    related 
Chronic oxalate nephropathy 
  Primary hyperoxaluria 
Renal colic 
Acute kidney injury  
Acute kidney injury  
Acute kidney injury, renal colic 
 
Acute kidney injury, renal colic 
 
Chronic kidney disease 
CKD, organ oxalosis   
 
Ca
++
pyrophosphate 
/Ca
++
phosphate 
Pseudogout, chondrocalcinosis, 
hemochromatosis, hyperparathyroidism 
Vascular calcification, calciphylaxis 
Warfarin calcification 
Dent`s disease, Nephrocalcinosis 
Acute monarthritis, periarthritis, bursitis 
 
Tissue ischemia, ischemic necrosis 
Tissue ischemia, ischemic necrosis 
Chronic kidney disease 
 
 
Intrinsic organic crystals or microparticles 
   
Adenine Adenine phosphoribosyl transferase 
deficiency 
Nephro-/urolithiasis, renal colic, chronic 
kidney disease 
 
Amyloid Amyloid-β in Alzheimer disease 
Amylin in diabetes 
Dementia 
Hyperglycemia 
 
Bile pigment Cholecysto-/docholithiasis 
Bile cast nephropathy 
Biliary colic, pancreatitis 
Acute kidney injury 
 
Cholesterol Atherosclerosis 
Cholesterol embolism 
Nonalcoholic steatohepatitis 
Cholesteryl ester storage disease 
Cholesterol granuloma 
Cholecysto-/docholithiasis  
Tissue ischemia, ischemic necrosis  
Ischemic necrosis 
Acute lipotoxic liver disease 
Chronic lipotoxic live disease 
Bone lesions 
Biliary colic 
 
Cystine Cystinosis CKD, urolithiasis, extrarenal    
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Light chains Myeloma cast nephropathy  
Crystalloglobulinemia 
Light chain Fanconi syndrome 
Crystal-storing histiocytosis 
Fibrillary glomerulonephritis 
Immunotactoid glomerulopathy 
Acute kidney injury  
Thrombotic microangiopathy 
Renal tubulopathy, CKD  
Renal tubulopathy, CKD 
Proteinuria, CKD 
Proteinuria, CKD 
 
Monosodium urate Gout 
 
Nephro-/urolithiasis 
Urate nephropathy 
Acute monarthritis, bursitis 
Chronic tophous gout 
Renal colic 
Acute kidney injury 
 
Myoglobin Myoglobin cast nephropathy Acute kidney injury  
Fibrillar α-synuclein Parkinson disease Motor symptoms (parkinsonism)   
Uromodulin Cast nephropathies Acute kidney injury  
 
Extrinsic crystals or particulates 
   
Asbestos Lung asbestosis, malignancy Pulmonary fibrosis, mesothelioma   
Drugs: 
Aciclovir,MTX, 
Indinavir,sulfadiazine 
Drug-related kidney injury Acute kidney injury, renal colic  
Hemozoin Malaria Hemolysis, SIRS  
Implants, implant 
debris particles 
Implant-related injury 
 
Monarthritis, aseptic osteolysis, 
foreign body reactions 
 
Occupational dusts: 
silica, asbestos, 
cotton, charcoal… 
Acute dust-induced lung injury  
Pneumoconiosis (silicosis, asbestosis, 
anthracosis, …) 
Dust-induced respiratory failure 
Lung fibrosis 
 
Tobacco smoke 
particulates 
Smoking-related COPD, emphysema Chronic respiratory distress  
Air pollutants Smog-related asthma, pneumonitis, 
COPD 
Acute respiratory distress  
Ca
++
: calcium, CKD: chronic kidney disease, SIRS: systemic inflammatory response 
syndrome, COPD: chronic obstructive pulmonary disease. Adapted from Mulay et. al. 20161 
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1.2 Gouty arthritis 
Gout is one of the most relevant crystallopathies. It is one of the most severe and 
frequent inflammatory rheumatic diseases. The pathology and symptoms visceral and chronic 
gout are less well-defined
3
 as gout is  most commonly presented as acute episodic arthritis 
event. Gouty arthritis, like all other clinical manifestations of gout, is triggered by the 
formation of needle-shaped MSU crystals. Due to the physiological conditions of uric acid 
overload either from excess oral uptake or massive cellular release of uric acid or from an 
impaired renal uric acid, MSU crystals are formed and deposited within joints. The final 
product of purine metabolism, uric acid when in excess, circulates as urate anion and 
combines with sodium ions to make MSU. Though hyperuricemia is one of the most 
important factors of gout onset, other factors such as temperature, pH, mechanical stress, 
cartilage components, and other synovial and serum factors may also contribute to the 
pathophysiological mechanisms
3,4
. MSU crystals are deposited in the form of tophi. Tophi 
resemble granulomas and cause trafficking of immune cells such as neutrophils, consistent 
with a role of inflammation in promoting tophus formation and remodeling
5
. These tophi 
usually develop in osteoarthritic toes and hand joints, suggesting a role of trauma, altered 
hydration (swelling), and connective tissue matrix structure and turnover. 
 
1.2.1 Onset and peak of acute gouty arthritis   
Gouty arthritis is characterized by a sudden onset within 2-4 hours that starts often 
during nighttime so that the patient wakes up with a painful joint early in the morning. The 
classical feature of gouty arthritis is an excruciating pain with articular and periarticular 
swelling and heat. When smaller joints are affected also redness may occur. Formation of 
MSU crystals is considered as an onset of gout that is followed by the massive infiltration of 
immune cells. The infiltrated neutrophils and monocytes ingest the MSU crystals at the site of 
tissue injury, which triggers a strong inflammatory response.  
 
1.2.2 Spontaneous resolution of gouty arthritis 
A characteristic feature of acute gout is its self-resolving nature after a few days. This 
spontaneous resolution suggests that the body turns on effective mechanisms to prevent an 
inflammatory response.  Mechanisms that are involved in shutting down gouty arthritis, such 
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as negative regulators of toll-like receptor (TLR) and cytokine signaling, clearance of 
apoptotic cells and aggregated NETs are described in more detail below.  
 
1.2.3 Pathophysiological mechanisms underlying gout onset and resolution  
MSU crystals act as a danger signal and trigger an inflammatory cascade including the 
activation of the NLRP3 inflammasome and the subsequent release of active interleukin (IL)-
1β via cleavage of pro-IL-1β
6
. Signaling for pro-IL-1β production occurs through pattern 
recognition receptors (PRRs) such as TLRs. These TLRs (e.g. lipopolysaccharide (LPS)) 
promote MyD88 signaling for the release of IL-1β by human mononuclear cells
7
 
8
 
9
. Evidence 
suggests that negative regulators of TLRs, cytokines, clearance of apoptotic cells and 
aggregated Neutrophil extracellular traps (NETs), contribute to the resolution of an acute gout 
attack. Inflammation induced via TLRs is a systemic and protective response to microbial 
pathogens or injury that needs to be fine-tuned and regulated, as uncontrolled inflammation 
can cause morbidity and mortality
10
. Negative regulators of TLR signaling have been 
identified to shut down inflammation. Soluble decoy TLRs (sTLRs) including sTLR-4 have 
the ability to extracellularly regulate TLR signaling by competing with TLR agonists, which 
leads to prevention of acute inflammatory responses
11
. A study reported that sTLR-4 inhibits 
nuclear factor (NF)-κB activation following LPS stimulation
12
. Pro-inflammatory cytokines 
are controlled by a number of other mechanisms including signal transducers and activators of 
transcription (STATs), cytokine inducible SH2-containing protein (CIS) and suppressors of 
cytokine signaling (SOCS)
13,14
. 
Data from an air pouch model of MSU crystal-induced inflammation indicated that 
both TLR2/4 and the ligand CD14 are involved in driving inflammation by mediating crystal 
uptake and pro-IL-1β priming
15
. IL-1β production and IL-1R signaling are crucial factors in 
driving the inflammatory response since mice deficient in the IL-1β or IL-1 receptor (IL-1R) 
showed MSU crystal-induced inflammation
6
.   
One classical mechanism involved in the resolution of acute gouty inflammation is the 
non-inflammatory phagocytosis of apoptotic neutrophils by macrophages
16,17
. The mechanism 
of apoptotic cell clearance by both macrophages and neutrophils has been linked to the 
production of transforming growth factor (TGF)β1
16,18
. In patients suffering from gout, 
TGFβ1 has been found in high levels in the synovial fluid during the resolution phase of acute 
inflammation
19
 
20
. Furthermore, in vitro studies have shown that TGFβ1 can down regulate 
the expression of IL-1R on hemopoietic cells
21,22
 suggesting a contribution of TGFβ1 during 
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gout resolution by limiting IL-1β signaling. IL-1R antagonist (IL-1Ra) as an endogenous 
mediator can function as a competitive inhibitor of IL-1R
23,24
. This is one of the mechanisms 
that the immune system uses to control IL-1β signaling. In vitro as well as in vivo data 
demonstrated that IL-1Ra has the ability to block the pro-inflammatory activities of IL-1 
cytokines, indicating a regulatory role for IL-1Ra in acute inflammation
25
 
26
 
27
. Elevated 
levels of IL-1Ra have been found in the synovial fluid from acute gout patients with resolving 
inflammation, suggesting a link between the release of IL-1Ra and the shutdown of IL-1β 
signaling
13
. Numerous reports have demonstrated that TGFβ1 can induce the secretion of IL-
1Ra by human circulating monocytes
28
 
29
 as well as neutrophils
30
 highlighting a role for IL-
1Ra in the resolution of gouty arthritis that was further confirmed by a number of clinical 
trials showing that the recombinant IL-1Ra Anakinra is effective at relieving acute gout 
attacks
31,32
 
33
. 
Furthermore, to limit the tumor necrosis factor (TNF) α induced inflammatory 
response, gout patients produce a higher level of the soluble TNF receptors (sTNFR)-I/II as 
well as IL-10
13
. Indeed, in vitro and in vivo studies show that the extracellular release of 
soluble sTNFR-I/II can act to inhibit TNFα signaling by sequestering TNFα, whereas 
retrovirally transfected IL-10 blocks MSU crystal-induced inflammation, including 
suppression of TNFα production in a murine air pouch model
34
. Serum sIL-6R levels are also 
increased in gout patient. However, it is not clear whether sIL-6R is pro-inflammatory due to 
the ability to activate cells that do not express IL-6R via trans-signaling
35
  or abrogates bone 
damage in chronic gout
36
.  
NETs released by activated neutrophils during the gout episode and MSU crystal-
NETs aggregate play an important role in the resolution of a gout attack
37
. The biology of 
generation, biochemical nature and importance of neutrophils and NETs in gout and other 
diseases is discussed in detail in the following section.  
 
1.3 Neutrophils 
Neutrophils are important effector cells of the immune system
38
. They are also known 
as polymorphonuclear leukocytes (PMNs). Neutrophils are the first responders to any kind of 
bacterial or fungal infection and were historically considered the nonspecific pus forming 
white blood cells. They have a short lifespan of around 5.4 days during which they continue a 
process of maturation and senescence
39
. Until the late 20th century short lived neutrophils 
were often ignored as immune cells compared to other long-lived immune cells like 
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monocytes. It was believed that neutrophils were incapable of the ‘more’ important functions 
of the immune system like antigen presentation, significant protein synthesis that contributes 
to the production of important immune modulating factors
40
. However, the neutrophil 
research over the past two decades changed these classical views and neutrophils are now 
considered as important immune cells involved in host defense mechanisms with their unique 
characteristics of chemotaxis, phagocytosis and lastly forming NETs.  
1.3.1 Neutrophil generation and circulation in blood stream 
In the bone marrow, neutrophils are generated from granulocyte-committed 
progenitors called myeloblasts
41
. Myeloblasts differentiate into promyelocytes and 
myelocytes following the neutrophil lineage. The cell division is restricted following the 
differentiation to metamyelocyte state from myelocytes. Neutrophils mature after this stage 
and their nuclei become segmented. After 5-6 days of maturation of the last myelocytic 
division, neutrophils enter the blood circulation
42
. The migration of neutrophils into the blood 
stream is a chemokine-regulated process. The chemokine receptor CXCR2 is upregulated in 
young neutrophils. The higher amounts of CXCL1 and CXCL2 (ligands for CXCR2) in bone 
marrow direct the neutrophils towards the blood circulation. Under physiological 
circumstances, the life span of neutrophils in the circulation is 6-8 hours. Neutrophil 
senescence involves upregulation of CXCR4 facilitating homing back to the bone marrow and 
other organs, where neutrophils undergo apoptosis and phagocytic clearance by 
macrophages
43
.  
 
1.3.2 Neutrophil migration and chemotaxis 
The neutrophil infiltration rate is increased in cases of infection or inflammation. 
Under inflammatory condition, cytokines such as G-CSF, IL-8, TNFα etc. or danger-
associated molecular patterns (DAMPs) endorse the migration of neutrophils towards the site 
of infection
44
. Neutrophil recruitment follows four steps known as a) tethering; initiated by 
binding of P-selectin and E-selectin present on endothelial surface to their ligands like P-
selectin glycoprotein ligand 1 (PSGL1) on neutrophil surface, followed by, b) rolling which is 
mediated by selectins followed by, c) crawling and d) transmigration, which depend on 
integrins
38
. Chemotaxis is a special mobility property of neutrophils. It is a process in which 
neutrophils get activated by specific chemoattractants that are released from the site of 
infection. These activated neutrophils sense a gradient of chemoattractants and migrate 
towards them
45
.  
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1.3.3 Neutrophil phagocytosis 
Neutrophils are the first immune cells reaching the site of infection and are the 
primary executors of rapid response against most of the fungal and bacterial infections. The 
recruited neutrophils engage with opsonized microbes by means of special receptors such as 
FcγRs and C-type lectin receptors
46
. This leads to the formation of a phagosome; a vacuole 
trapping the pathogens
47
. Apart from these receptors, neutrophils express wide ranges of other 
PRRs like TLRs, Nod-like receptors (NLRs) etc. that can recognize and interact with 
pathogens directly. This process of uptaking the pathogen is known as phagocytosis. 
Neutrophils are very efficient and rapid (less than 20s) phagocytes
48
. The phagocytosis 
process of neutrophils differs from that of macrophages, the well-known phagocytes. The 
phagosomes in neutrophils get rapidly fused with the neutrophil granules present in the 
cytoplasm. This process is regulated by cytosolic-free calcium in neutrophils to ensure 
efficient targeting and fusion of granules with phagosomes
49
. These granules contain 
hydrolytic enzymes as well as NADPH oxidases that initiate pathogen-killing mechanisms. 
The activation of NADPH oxidases leads to the oxidative burst and generation of reactive 
oxygen species (ROS) that can directly or indirectly kill the pathogens
50
. Patients of chronic 
granulomatous disease (CGD) are prone to infectious diseases as they lack one of the subunits 
of NADPH oxidase
40
. Thus, NADPH oxidase is a crucial player in host defense mechanisms 
of neutrophils. Uncontrolled release of neutrophil granular and oxidative products leads to 
tissue injury in a variety of infectious and inflammatory diseases
51
. 
 
1.3.4 Neutrophil extracellular traps (NETs) 
Neutrophil phagocytosis was considered as one of the major functional ability of 
neutrophils until 2004. The laboratory of Professor A. Zychlinsky discovered a novel property 
of neutrophils in 2004 that opened a new horizon in neutrophil biology research
52
. Upon 
bacterial infections, neutrophils release their genetic material and form web like structures 
made up of chromatin fibers (15-17nm diameter) decorated with granular enzymes like 
neutrophil elastase (NE), myeloperoxidase (MPO), cathepsin G etc. (50nm). These structures 
were called NETs
52
. 
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Figure 1: Induction of neutrophil extracellular traps. Neutrophils exclude their genetic material together with 
granular enzymes upon bacterial infection or in response to stimuli like micoorganisms, LPS, PMA, MSU 
crystals, cytokines or Chemokines. Adapted and modified from Desai, et. al 2016
53
.  
 
Over last decade, many laboratories have reported NETs in various bacterial, fungal, viral 
infections. In fact, extracellular trap formation is also reported in other cell types like 
eosinophils
54
, monocytes/macrophages
55
, mast cells
56
 as well as in the wide range of 
organisms from plants to animals like mice, cattle, horses, fish, cats, rabbits, invertebrates and 
humans
57
. Thus, the chromatin extracellular traps on a general note are also called 
‘extracellular traps’ (ETs)
58
. 
Various stimuli like phorbol myristate acetate (PMA), a wide range of bacterial 
pathogens (e.g. E.coli, S.aureus etc.), fungal pathogens (e.g. C albicans, Aspergillus 
fumigatus), LPS, complement c5a, different cytokines and chemokines like TNF, IL-6 can 
induce NET formation in vitro. Schauer et.al recently showed that NETs can also be formed 
during non-infectious disease conditions like gout
37
. In this case, neutrophils rapidly form 
NETs because of MSU crystals accumulation within the joints. The mechanisms by which 
NETs are formed in response to various stimuli could be different. However, the literature is 
still in its primitive stage and the exact molecular pathways involved in NET formation 
processes remain unclear till date.  
 
1.3.5 Signaling components in NET release 
Morphologically, once activated neutrophils undergo several changes to release NETs. 
Neutrophils become flat and multiple lobes of the nucleus are lost within one hour after 
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activation. This is followed by chromatin decondensation together with the simultaneous 
disintegration of granules. Around two hours after stimulation in vitro, the plasma membrane 
has ruptured leading to the release of NETs in extra-cellular space
52
. Thus, NET-forming 
neutrophils die at the end of this process. This process of neutrophil cell death during NET 
formation is called ‘NETosis’
59
. However, recent reports also suggest the possibility of 
neutrophils forming NETs without cell death
60
. Neutrophils in such cases release chromatin 
by forming specialized vacuoles, without plasma membrane rupture. Such NETs are named 
‘vital NETs’ (which will be discussed later).  Indeed, the literature is quite confusing when it 
comes to the signaling pathways that could be involved in NET formation procedures. 
ROS generated during the phagocytic process plays a crucial role in NET formation. 
The process of NET release requires the activation of NADPH oxidase via the Raf-MEK-
ERK pathway, ROS production, and upregulation of anti-apoptotic proteins
59
 
61
. Accordingly, 
neutrophils from humans or mice deficient in NADPH-oxidase cannot execute NET release
59
 
62
 
37
. But how do ROS exactly mediate NET formation? Several theories emerged to describe 
the involvement of ROS in “NETosis”, e.g. through NE, MPO, and histone deimination etc. 
Upon activation of neutrophils, ROS triggers the MPO-dependent proteolytic activity of NE
63
. 
  In the cytosol, NE degrades F-actin to arrest the actin dynamics of neutrophils before 
translocating to the nucleus where it degrades core histones e.g. H1 and then H4 and promotes 
chromatin decondensation
63
 
64
. MPO further synergizes with NE to induce chromatin 
decondensation independent of its enzymatic activity
64
. Accordingly, humans deficient in 
MPO as well as mice deficient in NE cannot form NETs
64
 
65
. However, the molecular 
mechanisms downstream to ROS production and upstream of NET formation are not clear. 
The reasons for the limited knowledge of NETs related biochemical pathways is the short life 
span of neutrophils, difficulties in studying NETosis in vivo as well as the inability to do 
genetic manipulations, and the lack of a neutrophil cell line that represent the physiology of 
primary neutrophils.  
 
1.3.6 NETs in host defense mechanism 
Entrapment by NETs. NETs can physically adhere to microbes to trap them. One possible 
mechanism of pathogen attachment to NETs could be the sticky nature of extracellular DNA 
molecules as well as electrostatic interactions. Pathogens like bacteria get trapped in NETs 
due to the electrostatic interactions between positively charged bacterial surfaces and 
negatively charged extracellular DNA present in NETs. Apart from these general 
Introduction   11 
 
mechanisms, specifically surfactant protein D, a C-type lectin-receptor (CLR), is known to 
form an intermediary bridge between neutrophil and pathogen that is crucial for their binding. 
Trapping bacteria. A wide range of bacteria including Streptococcus pneumoniae, 
Staphylococcus aureus, Escherichia coli are able to bind to extracellular DNA coming from 
NETs in vitro
66
 
60
. There are several in vivo pieces of evidence of bacterial capture by NETs. 
For example entrapment of Klebsiella pneumonia in NETs during lung infection in mice is 
reported using an imaging approach
64
. Furthermore, intravital microscopy of liver revealed 
E.coli captured by NETs
67
.  Several other laboratories have produced images of pathogen 
trapped in NETs using electron microscopy, immunofluorescence, spinning disc confocal 
microscopy as well as live-cell imaging approaches. In fact, the bacteria capture rate is 
increased by three to four folds after NET release independent of macrophage activities
60
. 
Several pathogens like Streptococcus pyogenes, Pneumococcus species, group A 
Streptococcus (GAS) and Staphylococcus aureus can synthesize endonucleases that are 
attached to their surfaces. These nucleases (e.g. DNase I) can cleave NETs made up of 
chromatin fibers and pathogens get released from the NETs
68
. Inhibiting DNase activity in 
infections from group A Streptococcus (GAS) significantly increases neutrophil-mediated 
pathogen clearance and reduces tissue necrosis. This could be a potential therapy for chronic 
diseases like sepsis.  
Trapping Fungi. NETs together with phagocytosis play an important role in host defense 
mechanisms against fungal infections. Using similar imaging approaches of 
immunofluorescence, scanning electron microscopy (SEM) techniques as well as 2-photon 
microscopy, several laboratories have provided visual evidence of the entrapment of different 
fungal species like Candida albicans, Aspergillus fumigatus etc
69
  
70
. 
Trapping Virus. Recent evidence suggests that apart from bacterial and fungal infections, viral 
infections can also be potent stimuli to release NETs from neutrophils
71
. The human 
immunodeficiency virus 1 (HIV-1) induces NETs in vitro via TLR7 and TLR8. Such studies 
have raised a tremendous interest in studying NETs, as they seem to have the capacity to 
capture a huge range of pathogens.  
1.3.7 Killing mechanisms by NETs  
After trapping and immobilizing pathogens, whether NETs can carry out direct 
pathogen killing functions or not is one of the most intriguing research question. The 
composition of NETs e.g. several granular proteases like NE, MPO, Cathepsin-G etc., 
antimicrobial peptides (the BPI protein and defensins), ion chelators (calgranulin), as well as 
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histones as a crucial component of the chromatin structure are well-known antimicrobial 
proteins
57
. Thus, it is likely that NETs can potentially carry out killing mechanisms by 
themselves in cases of different infections.  
Microbial killing by NETs. Histones from NETs are shown to be one of the strongest 
bactericidal components that can kill a range of different bacteria
72
. Apart from histones, the 
granular enzyme NE, one of the important NET components, can inactivate virulence factors 
by catalyzing their splitting in different bacterial species like Shigella flexneri, Salmonella 
typhimurium, and Yersinia enterocolitica. NETs can also potentially kill Pseudomonas in 
suspension during cystic fibrosis disease
73
. Some of the NET components like MPO have the 
potential to carry out independent killing processes e.g. in S. aureus infection. However, other 
groups also have shown less or no significant killing by NETs upon S. aureus infection
74
. 
Several in vitro studies showed that PMA induced NETs could stop C. albicans and 
Aspergillus growth through calprotectin mediated zinc chelation
75
. However, the role of 
histone-mediated NET killing is debated during fungal infections
76
. Interestingly, HIV-1 
virus-induced NETs could completely inactivate entrapped virions and this process was 
restricted by the addition of DNase leading to degradation of NETs
71
.  
Endothelium killing by NETs. Apart from pathogen killing mechanisms, several researchers 
have shown that NETs are involved in tissue injury in cases of sterile as well as non-sterile 
infections. LPS-activated platelets derived NETs can kill endothelial cells
67
. Especially 
extracellular histones coming from NETs can be cytotoxic for endothelial cells in several 
diseases like sepsis
77
. NETs in such cases can induce injury of the vasculature. Moreover, 
NETs are also important contributors to induce thrombosis as well as are associated with 
injury and inflammation in various autoimmune diseases like systemic lupus erythematosus 
(SLE) and anti-neutrophil cytoplasmic antibodies (ANCA) vasculitis. Various NET-
associated diseases are discussed in detail in the following section. 
 
 
1.3.8   NETs in autoimmune diseases 
ANCA vasculitis and Systemic Lupus Erythematosus 
Patients with an autoimmune disease or SLE possess increased levels of ANCAs, anti-
nuclear antibodies against e.g. histones, DNA, and ribonucleoproteins
60
. NETs play a crucial 
role in the disease progression in these disorders. Infection-induced NETs are major resources 
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of extracellular histones and DNA, neutrophil enzymes and several antimicrobial peptides as 
primary antigenic components in SLE
78
. Furthermore, it is recently observed that the blood of 
SLE patients contains a population of low-density granulocytes, which can undergo rapid 
NET formation ex vivo
79
. Components like DNA that release from NETs activate 
plasmacytoid dendritic cells to secrete interferon (IFN)-α). IFN-α promotes auto reactivity 
and expands the SLE progression. As a positive loop, IFN-α primes neutrophils to release 
NETs, which can activate DCs
80
. This positive feedback loop plays an important role in the 
disease progression of SLE and ANCA vasculitis. Moroever, the SLE patient serum possesses 
elevated levels of DNase I activities, lower expression levels of DNase I inhibitors and high 
levels of autoantibodies that protect NETs from DNase degradation
78
. These patients may 
later develop kidney disorders like lupus nephritis or severe glomerulonephritis. Apart from 
therapies involving anti-IFN-α strategies, NETs are the potential therapeutic targets for the 
treatment of SLE and ANCA vasculitis
60
.  
Rheumatoid arthritis  
Rheumatoid arthritis (RA) is a systematic autoimmune disease that primarily occurs in 
the synovial joints. NETs are a major inflammatory component of the disease and are 
primarily found in synovial fluids (SF) of joints, under the skin and in rheumatoid nodules 
during RA episodes
60
. NETs contain high levels of citrullinated proteins that can be adverse in 
RA because RA patients also have elevated levels of anti-citrullinated peptide antibodies 
(ACPAs) in SF
81
. Furthermore, ACPA containing SF can prime neutrophils from RA patients 
to induce NETs
81
. Thus, NETs play a crucial role in disease progression of RA. It is possible 
that within NET components, histones are the important molecules to undergo citrullination 
process and hence can be represented as an important source of citrullinated proteins in the 
joint of RA patients. In fact, RA patients exhibit increased levels of anti-PAD4 antibodies and 
PAD4 expression
82
. Thus, citrullinated histones may be a good diagnostic marker to study 
NETs in RA.  
 
1.3.9 NETs in gout  
Recent studies demonstrated that in vitro neutrophils form NETs following stimulation 
with MSU crystals, that was further confirmed after analysis of synovial fluid and tissue 
sections from patients suffering gout in vivo
83
 
84
. Neutrophils ingest MSU crystals leading to 
NETosis, whereby DNA is rapidly released into the extracellular space. The released DNA 
fragments form traps, which in turn cluster around MSU crystals to generate aggregated NETs 
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(aggNETs)
37
. These large DNA/MSU crystal structures, also known as gout tophi, can only 
form, when neutrophils are present in high numbers, usually at the later phase of a gout 
attack
85
. Functional studies have shown that aggNETs can degrade and inactivate pro-
inflammatory cytokines, such as IL-1β, TNFα, IL-6, and the chemokine monocyte 
chemoattractant protein (MCP)-1 via neutrophil serine proteases
37
. It is known that NETosis 
and aggNETs are dependent on the oxidative burst in promoting inflammation and tissue 
damage
37
. In contrast, studies now suggest an anti-inflammatory function of ROS in 
facilitating the formation of aggNETs to trap and degrade inflammatory mediators in MSU 
crystal-induced inflammation
37
 as well as other autoimmune diseases such as collagen-
induced arthritis
86,87
. Moreover, human monocyte-derived macrophages from healthy 
volunteers efficiently ingest NETs via an immunologically silent process
88
. Together, these 
data underline the molecular process of aggNETs and the phagocytosis of NETs by 
macrophages as possible mechanisms in shutting down inflammation in gouty arthritis.  
To summarize, NETs play a crucial role in most of these diseases as mentioned above. 
Whether neutrophils that form NETs also undergo cell death during this process is still largely 
unexplored.  
 
1.4 Regulated cell death 
Cell death is a crucial phenomenon in physiology to maintain the homeostasis and 
functionality of all tissues.  To understand the mechanisms of cell death pathways has been 
one of the strong interests of molecular biologists and biochemists for a long time. Several 
biochemical pathways are now known to regulate cell death modes in different cell types in 
different diseases as well as under normal conditions. Typically, the cell death modes are 
classified in two categories: 1) programmed form of cell death, 2) non-programmed form of 
cell death
89
. According to the Nomenclature Committee for Cell Death, the adjective 
‘programmed’ is thought to be involved in maintaining physiological processes such as 
developmental processes as well as maintenance of tissue homeostasis. Whereas the adjective 
‘regulated’ is used to identify cell death events that rely on definite cellular and molecular 
mechanisms. Traditionally, apoptosis is an example of such programmed regulated form of 
cell death. The non-programmed form of cell death can also be called ‘accidental cell death’. 
Typically, this mode of cell death is thought to not be dependent on specific molecular 
pathways like programmed cell death pathways. Necrosis was believed to be such form of cell 
death, which was always conceived as pharmacologically incontrollable. Necrosis was 
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thought to be mostly resulting due to harsh environmental conditions like severe changes in 
temperature, pH, osmotic pressure etc. As necrosis was always considered as an accidental 
cell death without involving specific molecular mechanisms, it was considered as ‘non-
regulated’ form of cell death.   
 
1.4.1 Apoptosis 
Apoptosis is a caspase-dependent mode of programmed cell death that is regulated by 
two distinct biochemical pathways: i) intrinsic pathway ii) extrinsic pathway (figure 2). A 
wide range of injury and intracellular stress signals like DNA damage, oxidative stress, 
cytosolic calcium overload, endoplasmic reticulum (ER) stress promote mitochondrial outer 
membrane permeabilization (MOMP) that leads to the release of mitochondrial components 
e.g. cytochrome C, Smac, Omi/HtrA2 etc
90
 
91
.  This leads to activation of caspase 3 dependent 
intrinsic pathways of apoptosis. Whereas, various extracellular stress signals e.g. different 
injury associated cytokine release, DAMPs, pathogen-associated molecular patterns (PAMPs) 
induce the extrinsic pathway of apoptosis. These danger signals associate with different 
transmembrane receptors viz. death receptors (DRs), TLRs or NLRs and further activate 
caspase 8. The proteolytic activation of caspases during apoptosis cause morphological 
changes in apoptotic cells that include chromatin condensation, nuclear fragmentation 
(karyorrhexis), plasma membrane blebbing, cellular shrinkage (pyknosis) leading to the 
formation of apoptotic bodies 
92
, which are cleared by local phagocytes without triggering 
immune responses due to the leakage of intracellular components.   
 
 
 
 
 
Introduction   16 
 
 
 
 
 
 
Figure 2: Different modes of regulated cell death pathways (RCD). RCD can be further divided in two 
categories. A) Caspase dependent RCD that includes cell death modes of apoptosis and caspase-1/caspase-11 
dependent pyroptosis. B) Caspase independent RCD including necroptosis, mitochondrial permeability transport 
(MPT)-regulated necrosis (RN), Pathanatos, Ferroptosis and NETosis. Adapted from Linkermann et. al 2014
93
.  
 
1.4.2 Regulated necrosis 
In contrast to apoptosis, necrosis was traditionally considered to be a non-programmed 
mode of cell death occurring as a result of some physicochemical insult. However, in the last 
decade several genetic evidences
94
 as well as pharmacological inhibitors
95
 have identified the 
involvement of defined biochemical signaling pathways that leads to plasma membrane 
rupture and cellular leakage as well as cellular swelling and termed them regulated necrosis 
(RN)
89
. Depending on the kind of signaling pathway involved, regulated necrosis is 
categorized into necroptosis, ferroptosis, mitochondria permeability transition (MPT) RN 
pyroptosis and parthenatos (figure 2). They are described in detail in the following section. 
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Necroptosis 
Necroptosis is a regulated mode of cell death that is driven by the protein cascade of 
receptor interacting protein kinase 1 (RIPK1) and RIPK3, and MLKL
96
. This cascade gets 
activated in response to various DAMPs, virus, DRs, and TLRs
96,97
.  It is one of the most 
studied pathways of regulated necrosis. Upon injury, RIPK1 gets phosphorylated, which 
further leads to downstream events of RIPK3 and MLKL phosphorylation. The 
phosphorylated MLKL is translocated to the plasma membrane, where it is thought to be 
associated with pore formation within the plasma membrane and thus executing cell death
98
. 
Various chemical inhibitors like necrostatin-1
95
 and necrosulfonamide (NSA)
99
 are known to 
inhibit necroptosis in certain injury and diseases. 
Ferroptosis 
Ferroptosis is a form of RCD that is dependent on intracellular iron metabolism
100
. It 
was identified in RAS-transformed tumour cells, when treated with a lethal molecule called 
erastin. The small molecule erastin induces ferroptosis by inhibiting XC
−
 Cystine/Glutamate 
antiporter that allows the exchange of extracellular L-Cystine and intracellular L-Glutamate 
across the plasma membrane
100
. This antiporter is required for glutathione biosynthesis. Upon 
depletion of intracellular glutathione, glutathione peroxidase 4 (GPX4) cannot degrade 
accumulating lipid peroxides, resulting in ROS-mediated lipid peroxidation and cell death
101
. 
Ferrostatin 1 is a chemical inhibitor of ferroptosis, however, the mechanism of action of this 
compound is yet unknown
100
.   
Mitochondrial permeability transition-related necrosis 
MPT means a condition in which the permeability of the inner mitochondrial 
membrane is increased, which drives a massive influx of water molecules due to osmotic 
forces
102
. This can 1) disrupt biosynthetic and bioenergetic mitochondrial functions that 
depend on the transmembrane potential (Δψm), 2) release various mitochondrial proteins, 
which can contribute to activation of both apoptotic cascade and regulated necrosis cascade 
(MPT-RN)
102
. MPT together with mitochondrial outer membrane permeabilization (MOMP) 
represents one of the crucial gateways to initiate apoptotic process in several 
pathophysiological conditions. During MPT-RN, the mitochondrial matrix protein called 
cyclophilin D (CYPD) control the MPT pore
103
. Immunosuppressive compounds, such as 
cyclosporine A or sanglifehrin A inhibit CYPD and thus, inhibit MPT-RN, independently of 
their immunosuppressive activities
104
. This mode of RCD is involved in different types of 
ischemia-reperfusion injury as well as acute organ failure
105
 .  
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Pyroptosis 
The term pyroptosis was given for a special way of macrophage cell death upon 
Salmonella enterica infections
106
. Pyroptosis is regulated cell death that involves caspases that 
are different than caspases involved in apoptotic cascades. Pyroptosis depends on caspase 1 
and caspase 11. It involves activation of inflammasomes and is followed by caspase-11 
activation
107
. This mode of immune cell death results in a large amount of IL-1β and IL-18 
secretion. In this way, pyroptotic cells are usually associated with higher inflammation rates 
and a highly immunogenic mode of cell death
108
. Immune cells like activated macrophages as 
well as dendritic cells die by switching on pyroptosis. This form of RCD was demonstrated to 
be associated with various bacterial and viral infections
108
 
109
.  
Parthanatos 
Ted and Valina Dawson demonstrated a regulated necrosis pathway called 
‘parthanatos’ that depends on the hyper-activation of poly (ADP-ribose) (PAR) polymerase 1 
(PARP1)
110
. PARPs like PARP1 get activated upon DNA breaks induced by ultraviolet light, 
ROS, Ca
2+
 signalling pathway
110
. PARP1, when over-activated, can lead to parthanatos. 
Several preclinical pieces of evidence suggest that PARP inhibition may serve as a potential 
target for the treating various cancers, vascular or neurodegenerative diseases
111
.  
According to the new categorization, NETosis, cell deaths a result of NET formation, 
was also considered to be part of this RCD. However, unlike the above RCD, the molecular 
mechanisms involved in NETosis remain elusive.    
1.5 Neutrophil death 
1.5.1 NETosis: NET formation in association with cell death 
NETs were first described using extensive cell imaging techniques after stimulation of 
human neutrophils with phorbol 12-myristate 13-acetate (PMA) or IL-8
52
. Three years later, 
the same group reconfirmed an observation made in 1996 that neutrophils undergo a distinct 
form of cell death following PMA stimulation, which is neither apoptosis nor necrosis, and 
named it “NETosis”
112
. “NETosis”, unlike apoptosis or necrosis, was described to involve 
expansion of the nuclear material, chromatin decondensation, nuclear envelope disintegration, 
subsequent mixing of cytoplasmic and nuclear components followed by plasma membrane 
rupture and release of NETs
112
 
113
. Since then, NET release was considered to imply 
neutrophil death and the term “NETosis” was established in the literature. In the last decade, 
researchers extensively studied “NETosis” mostly using conventional bioassays, which do not 
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distinguish the two phenomena NET release and neutrophil death (Table 1). For example, the 
most widely used assays for NET release, Picogreen and Sytox assays, involve detection of 
cell-free DNA as the main principle. However, since these methods also detect necrosis-
related passive release of chromatin, it is difficult to distinguish this process from a proactive 
chromatin expulsion
114
 
115
. Some researchers used lactose dehydrogenase (LDH) assay to 
measure NET formation in vitro
116
. However, cells and tissues release LDH upon toxic or 
injury-related damage
117
, making this assay highly unspecific for the distinguishing NET 
formation and cell death.  
Furthermore, detection of histone deimination (citrullination of histones) by 
immunoblots or immunohistology was considered as an indicator for NET formation, since 
histone deimination induces chromatin decondensation, which is an essential step during NET 
release
59
. Several studies implicated the involvement of peptidyl-arginine deiminase 4 
(PAD4) in NET formation
59
 
118
. PAD4 is the enzyme required for citrullination of histones 
and chromatin decondensation during NET formation
59
. Accordingly, chemical inhibition of 
PAD4 using Cl-amidine impaired NETosis in animal models of anti-GBM disease or lupus 
nephritis
77
 
119
. However, the requirement of PAD4 in NET formation is a debated question 
owing to the unspecific effects of Cl-amidine for PAD4
120,121
, as well as the inconsistencies 
observed in NET formation in Pad4-deficient mice. For example, Pad4-deficient mice 
displayed impaired NET formation during necrotizing fasciitis
117
 but succumbed to influenza 
pneumonitis, which involves influenza virus-induced NETs in the lung
122
. These disparities 
suggest that the involvement of PAD4 in NET formation depends on the stimulus. Indeed, it 
is shown that some stimuli e.g. calcium ionophores activate PKCζ, and thus PAD4, as well as 
PMA activate PKCα and, thus, inhibit PAD4
123
, while both stimuli still induce NET release.  
Another widely used technique for assaying NET formation is ‘microscopy’. 
Researchers have used immunofluorescence (IF), confocal, as well as electron microscopy 
techniques to characterize either the presence of NETs, by detecting the co-localization of 
neutrophil-specific proteins and DNA
59
, or the morphological appearances of NETs
52
 
59
.  
However, the main drawback of using these techniques is the need for cell fixation 
prior to microscopic examinations. Therefore, this technique cannot really distinguish the 
process of NET formation and cell death. Researchers also used enzyme-linked 
immunosorbent assay (ELISA), a technique to detect complexes of neutrophil-specific 
proteins and DNA, e.g. MPO-DNA or NE-DNA complexes etc
114
 
115
 
116
 as an indicator of the 
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NET formation. However, although these assays confirm the presence of NETs, they fail to 
distinguish the NET formation and cell death. 
Table 2.  NET evaluation and bioassay characteristics 
LDH: Lactate dehydrogenase, MPO: Myeloperoxidase, NE: Neutrophil elastase, WB: Western Blot, IF: 
Immunofluorescence, DAPI: 4', 6-diamidino-2-phenylindole, CitH3: Citrullinated histones etc.  Table adapted 
from Desai et. al 2016
53
 
 
In contrast, time-lapse video microscopy allowed observing NET formation
59
. 
Neutrophils are imaged using a combination of nuclear (Sytox, Hoechst, Pico), cytoplasmic 
(calcien, granular dyes e.g. NE) and cell death dyes (propidium iodide, annexin V) making it 
feasible to identify different components of NET formation process and cell death, in a 
manner dependent on each stimulus and time course
59
. Moreover, Zhao W. et. al. reported the 
Method 
 
Target Identify NETs Distinguish NET 
release and Cell 
death 
Ref. 
PicoGreen/ 
Sytox assay 
(Spectrofluorometry) 
 
Extracellular and dead 
cell DNA 
No No 
112,124
 
LDH assay 
(Spectrometry) 
 
LDH release No No 
113
 
MPO-DNA complexes  
 
(Capture ELISA) 
MPO and DNA Yes No 
114,115
 
NE-DNA complexes  
 
(Capture ELISA) 
NE and DNA Yes No 
125
 
Histone deamination 
 
(IF Microscopy, WB) 
Citrullinated histones Yes No 
117,126
 
Morphology 
 
(IF and Confocal 
Microscopy) 
 
DNA (DAPI, Sytox) 
 
Granule protein (MPO, 
NE, CitH3) 
 
Yes 
 
Yes 
No 
 
No 
 
52,59,12
3
 
Micromorphology 
(Electron Microscopy) 
 
Ultrastructure of nuclei / 
cytoplasm 
 
Yes No 
52,59
 
Live cell imaging 
(Time Lapse 
Microscopy) 
DNA (Sytox, Hoechst, 
etc), Cytoplasm (Cell 
tracking dye) 
 
Yes Yes 
59
 
Combination of 
Microscopy and Flow 
Cytometry  
Subcellular morphology Yes Yes 
127
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use of a combination of microscopy and flow cytometry for simultaneous detection and 
quantification of NET formation
127
. Interestingly, this technique also claimed to distinguish 
between NET formation with and without cell death
127
. Together, as few methods are suitable 
to clearly distinguish NET release from neutrophil death, these two phenomena often seem 
connected and are referred to as “NETosis”. However, as neutrophils surviving NET release 
have been documented and when NET release upon certain stimuli can be inhibited with 
`conventional` cell death inhibitors it seems obvious that the term “NETosis” is no longer 
universally appropriate. 
 
1.5.2 NET release without neutrophil death 
Neutrophils can form NETs upon certain kind of bacterial infections in vivo without dying 
60
. 
Pilsczeck et. al. reported that upon infection with Staphylococcus aureus, neutrophils formed 
NETs within 5-60 minutes without dying and were independent of ROS production. These 
early NETs were also observed in vivo using spinning disk microscopy within 10 min after 
subcutaneous injection of S. aureus 
66
. Obviously, during this process, the neutrophil`s plasma 
membrane remains intact and the chromatin was released from the nucleus via intracellular 
vesicles that fused with the outer membrane to release NETs in the extracellular space 
128
. 
NET release without neutrophil death was also observed within 30 minutes after stimulation 
of neutrophils with bacteria, fungi or LPS 
66,67,128,129
. This rapid NET formation is mediated 
by the complement system, TLR2 or fibronectin 
128,129
. Importantly, neutrophils releasing 
such NETs rapidly remained motile in-vivo, retaining the possibility to multitask during the 
early infection phase 
128
. This rapid NET release indicates the dynamic functions of neutrophil 
to trap bacteria in NETs, while the anuclear neutrophils are still able to contribute to bacterial 
killing by phagocytosis
128,130
.   
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Figure 3. Neutrophil death and NET formation. Aging neutrophils die by apoptosis whereas stimuli like 
crystals, PMA, LPS, and TNF induce NET release associated with neutrophil death, referred to as necroptosis. 
Neutrophils are also known to release NETs without death, referred to as vital NET formation, upon certain 
bacterial stimuli, e.g. S. aureus. Inhibitors of necroptosis, e.g. RIPK1 and MLKL inhibitors as well as inhibitors 
of ROS, proteases and PAD can block NET release associated with neutrophil death. Figure adapted from Desai 
et. al 2016
53
. 
Furthermore, S. aureus-induced rapid NETs are composed of histones, confirming that 
the NETs are originated from the nuclei, without involving mitochondrial DNA 
66
. While 
other stimuli like LPS, complement factor C5a induce NETs release from mitochondrial DNA 
together with granular enzymes after GM-CSF priming in a ROS-dependent manner 
131
. 
Interestingly, S. aureus rapidly induced NET release even before ROS were generated, 
whereas Aspergillus-induced NETs independent of ROS 
66,129
. Moreover, statins (cholesterol-
lowering drugs) have been reported to block the oxidative burst of PMNs, still enhancing 
NET formation against S. aureus 
55
. Growing evidence demonstrated that NET formation with 
cell death involves oxidant generation, whereas rapid NET formation without cell death may 
or may not involve oxidant generation (figure 3). For example, stimuli like PMA or bacteria-
induced ROS-dependent NET formation and cell death, while stimuli like ionomycin or 
certain bacterial/fungal products induced ROS-independent rapid NET formation without cell 
death
132
. 
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Table 3: Definition of important NET-related terms 
RIPK = receptor interacting protein kinase, MLKL = mixed lineage kinase domain-like. Adapted from Desai et. 
al 2016
53
.  
 
1.6 The necroinflammation concept   
At the end of cellular necrosis, various DAMPs are released that in turn can initiate 
inflammatory tissue responses in neighboring healthy cells. Furthermore, the same 
inflammatory responses within tissue cells lead to necrotic cell death of the same, leading to 
release of more DAMPs. This auto-amplification look between cell necrosis and 
inflammatory responses is known as necroinflammation
93
. The auto-amplification loop of 
necroinflammation consists of two mechanisms that enforce each other, i.e. DAMP-mediated 
Term Definition 
NET Neutrophil extracellular traps are chromatin expulsed from neutrophils 
decorated with nuclear and cytosolic components such as proteolytic enzymes   
NETting The process of NET formation by groups of neutrophils, e.g. in pus, tophus or 
thrombus formation   
NETosing The neutrophils/PMNs capable for forming NETs  
NETosis NET formation in association with death of the neutrophil, common in pus, 
tophi or thrombosis, but the term does not specify the mode of cell death  
Suicidal 
NETosis  
NET formation in association with the death of the neutrophil, but the term 
does not specify the mode of cell death. “Suicidal” implies that the trigger for 
death is intrinsic, which is usually not the case. Imprecise term that is to be 
avoided 
Lytic NETosis   NET formation by pathogen-induced lysis of neutrophils e.g. S. aureus 
Vital NETosis  NET formation without the death of the neutrophil. As “Osis” implies death 
and “Vital” implies alive the term is a contradiction in itself and should be 
avoided 
Neutrophil 
necroptosis 
Neutrophil death that can be blocked by inhibitors of the necroptosis pathway 
(RIPK3-MLKL) 
Neutrophil 
apoptosis 
Neutrophil death that can be blocked by inhibitors of caspase 3, 8, and 9 
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activation of innate immunity and cytokine-induced regulated cell necrosis. Together, the 
auto-amplification loop of necrosis and inflammation drives the crescendo from local 
inflammatory tissue injury to acute organ dysfunction, organ failure or eventually up to a 
systemic inflammatory response syndrome and multiorgan failure
133
. 
 Gouty arthritis is a strong inflammatory disease initiated by the accumulation of MSU 
crystals in synovial fluid. This leads to a strong inflammatory response and massive 
infiltration of immune cells like neutrophils and macrophages. These immune cells especially 
neutrophils upon the contact with MSU crystals may undergo necrotic cell death (NET-
associated cell death) releasing DAMPs in extracellular space like DNA and histones. This 
may further trigger inflammation, setting up the loop of necroinflammation in the synovium 
and leading to further tissue damage.  
NETosis was first described as form of neutrophil death that was different from 
classical apoptosis and necrosis
59
. In the last decade, cell biology domain re-classified the 
classical cell death categories of apoptosis and necrosis into a myriad of novel categories 
defined by distinct causative signaling pathways
134
. Whether NETosis is one of those or a 
distinct category has remained unclear. The immunology domain observed that leukocyte-
death-upon-activation is a common phenomenon not only for effector T cells but also for 
inflammasome-activated macrophages and dendritic cells
135
 
126
. Furthermore, NET formation 
was described to occur also without immediate neutrophil death
60
, which was quickly referred 
to as “vital NETosis”
60
 
127
 (figure 3), although this term is an obvious contradiction in itself 
(Table 2). Such nomenclatures in the part mirror and potentially account for the general 
confusion about the evolving spectrum of evidence on NET formation. Therefore, the scope 
of this thesis is to decipher the molecular mechanisms involved in NET formation and 
neutrophil death, especially in crystallopathies.  
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2. Hypotheses/objectives 
Based on above literature we hypothesized that- 
1. Different crystals, irrespective of their nature, induce NET formation and neutrophil 
death. 
Various crystallopathies are associated with strong inflammatory responses.  
2. Crystal-induced NET formation and neutrophil death involve regulated necrosis 
pathways.  
3. Molecules involved in the regulated necrosis pathways will serve as potential 
therapeutic targets for the treatment of crystallopathies e.g. gout. 
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3. Material and Methods 
3.1 Instruments and Chemicals 
3.1.1 Instruments 
Balance:  
Analytic Balance, BP 110 S Sartorius, Göttingen, Germany 
Mettler PJ 3000 Mettler-Toledo, Greifensee, Switzerland 
 
Cell Incubators: 
 
Type B5060 EC-CO2 Heraeus Sepatech, München, Germany 
 
Centrifuges: 
 
Heraeus, Minifuge T VWR International, Darmstadt, Germany 
Heraeus, Biofuge primo Kendro Laboratory Products GmbH, Hanau, 
Germany 
Heraeus, Sepatech Biofuge A Heraeus Sepatech, München, Germany 
 
ELISA-Reader: 
 
Tecan, GENios Plus Tecan, Crailsheim, Germany 
 
Fluorescence Microscopes: 
 
Leica DMi8 Leica Microsystems, Cambridge, UK 
Olympus BX50 
Zeiss observer microscope 
Olympus Microscopy, Hamburg, Germany 
Zeiss, Germany 
Zeiss Libra 120 TEM Zeiss, Germany 
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Spectrophotometer: 
Beckman DU® 530 Beckman Coulter, Fullerton, CA, USA 
 
TaqMan Sequence Detection 
System: 
 
ABI prism ™ 7700 sequence 
detector 
PE Biosystems, Weiterstadt, Germany 
 
Other Equipments: 
 
Nanodrop PEQLAB Biotechnology GMBH, Erlangen, Germany 
Cryostat RM2155 Leica Microsystems, Bensheim, Germany 
Cryostat CM 3000 Leica Microsystems, Bensheim, Germany 
Homogenizer  ULTRA-TURRAX IKA GmbH, Staufen, Germany 
Microtome HM 340E Microm, Heidelberg, Germany 
pH meter WTW WTW GmbH, Weilheim, Germany 
Thermomixer 5436 Eppendorf, Hamburg, Germany 
Vortex Genie 2™ Bender & Hobein AG, Zürich, Switzerland 
Water bath HI 1210 Leica Microsystems, Bensheim, Germany 
 
3.1.2 Chemicals and reagents 
RNeasy Mini Kit Qiagen GmbH, Hilden, Germany 
RT-PCR primers PE Biosystems, Weiterstadt, Germany 
SYTOX green assay Life Technologies, Eugene, OR, USA 
Pico green dsDNA assay 
ROS assay: DCFDA dye 
LDH cytotoxicity assay 
Life Technologies, Eugene, OR, USA 
Sigma lifesciences, Germany 
Roche, Germany 
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MTT viability assay 
TO-PRO®-3Iodide  
Sigma-Aldrich, Steinheim, Germany 
Life Technologies, Eugene, OR, USA 
 
Cell culture:  
DMEM-medium Biochrom KG, Berlin, Germany 
RPMI-1640 medium GIBCO/Invitrogen, Paisley, Scotland, UK 
FSC Biochrom KG, Berlin, Germany 
Dulbecco’s PBS (1×) PAA Laboratories GmbH, Cölbe, Germany 
Trypsine/EDTA (1×) PAA Laboratories GmbH, Cölbe, Germany 
Penicillin/Streptomycin (100×) PAA Laboratories GmbH, Cölbe, Germany 
 
Antibodies: 
 
Ripk3 Abcam, Cambridge, UK 
Ripk1 Abcam, Cambridge, UK 
p-MLKL(human) Merck Millipore, Germany 
Histone 
Histone IgG  
Cell signaling, Danvers, MA 
clone BWA3, Immunomedics, NJ, USA 
Neutrophil elastase Santa Cruz Biotechnology, Santa Cruz, CA 
Myeloperoxidase Cell signaling, Danvers, MA 
Cit-H3 Cell signaling, Danvers, MA 
DNA antibody Roche, Mannheim, Germany 
HRP linked Anti-Rabbit secondary 
Ab 
Cell signaling, Danvers, MA 
HRP linked Anti-Mouse secondary 
Ab 
Cell signaling, Danvers, MA 
HRP linked Anti-Goat secondary Ab Dianova, Hamburg, Germany 
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β-Actin Cell signaling, Danvers, MA 
Antihuman CD15 BD Bioscience, Germany 
Antihuman CD11B BD Bioscience, Germany 
Antihuman CD66b Biolegends, Germany 
 
Elisa Kits: 
 
mouse IL-1ß R &D Systems, Minneapolis, MN, USA 
mouse TNF-α Biolegend, San Diego, CA 
 
Inhibitors 
Necrostatin-1 
Necrostatin-1s 
Necrosulfanamide 
Ferrostatin-1 
Pan caspase inhibitor zVAD 
PAD inhibitor-Cl amidine 
 
Crystals 
Calcium oxalate 
Monosodium urate 
Calcium phsphate 
Calcium pyrophosphate (CPP) 
Cystine 
Myoglobin 
Cholesterol 
Crocidolite Asbestos 
 
Enzo Life Sciences, Lörrach, Germany 
Biovision, Milpitas, CA 
Millipore, Schwalbach, Germany 
CalBiochem, Germany 
Enzo Life Sciences, Lörrach, Germany 
Merck Millipore, Germany 
 
 
Alfa Aesar, Germany  
Invivogen, Toulouse, France 
Chem Cruz 
Invivogen, Toulouse, France 
Sigma life sciences, Germany 
Sigma life sciences, Germany 
Invivogen, Toulouse, France 
SPI-CHEM 
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Silica 
Alum 
TiO2 20nm 
TiO2 80nm 
 
Chemicals: 
Alfa Aesar 
Invivogen, Toulouse, France 
Io-li-tec nanomaterials, Heilbronn, Germany 
Io-li-tec nanomaterials, Heilbronn, Germany 
 
PMA Sigma–Aldrich, Steinheim, Germany 
LPS InvivoGen, San Diego, CA 
TNFa Immunotools, Germany 
Histone Roche, Germany 
Acetone Merck, Darmstadt, Germany 
AEC Substrate Packing Biogenex, San Ramon, USA 
Bovines Serum Albumin Roche Diagnostics, Mannheim, Germany 
 Skim milk powder Merck, Darmstadt, Germany 
DEPC Fluka, Buchs, Switzerland 
DMSO Merck, Darmstadt, Germany 
EDTA Calbiochem, SanDiego, USA 
30% Acrylamide Carl Roth GmbH, Karlsruhe, Germany 
TEMED Santa Cruz Biotechnology, Santa Cruz, CA 
Eosin Sigma, Deisenhofen, Germany 
Ethanol Merck, Darmstadt, Germany 
Formalin Merck, Darmstadt, Germany 
Hydroxyethyl cellulose Sigma-Aldrich, Steinheim, Germany 
HCl (5N) Merck, Darmstadt, Germany 
Isopropanol Merck, Darmstadt, Germany 
Calcium chloride Merck, Darmstadt, Germany 
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Calcium dihydrogenphosphate Merck, Darmstadt, Germany 
Calcium hydroxide Merck, Darmstadt, Germany 
MACS-Buffer Miltenyl Biotec, Bergisch Gladbach, Germany 
Beta mercaptoethanol Roth, Karlsruhe, Germany 
Sodium acetate Merck, Darmstadt, Germany 
Sodium chloride Merck, Darmstadt, Germany 
Sodium citrate Merck, Darmstadt, Germany 
Sodium dihydrogenphosphate Merck, Darmstadt, Germany 
Potassium chloride Merck, Darmstadt, Germany 
Dextran 
Lymphoprep (density of 0,177g/mL) 
Sigma Aldrich, St.Louis, USA 
Stemcell, Germany 
RIPA buffer Sigma, Deisenhofen, Germany 
Chemiluminescence system Amersham, Buckinghamshire, UK 
Penicillin Sigma, Deisenhofen, Germany 
Roti-Aqua-Phenol Carl Roth GmbH, Karlsruhe, Germany 
Streptomycin Sigma, Deisenhofen, Germany 
Tissue Freezing Medium Leica, Nussloch, Germany 
Trypan Blue Sigma, Deisenhofen, Germany 
Oxygenated water DAKO, Hamburg, Germany 
Xylol Merck, Darmstadt, Germany 
 
Miscellaneous: 
 
PVDF membrane Millipore, Schwalbach, Germany 
Microbeads Miltenyl Biotech, Germany 
Preseparation Filters Miltenyl Biotec, Bergish Gladbach, Germany 
Super Frost® Plus microscope slides  Menzel-Gläser, Braunschweig, Germany 
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Needles BD Drogheda, Ireland 
Pipette’s tip 1-1000μL Eppendorf, Hamburg, Germany 
Syringes Becton Dickinson GmbH, Heidelberg, Germany 
Heparin tubes S-monovette, Germany 
Plastic histocasettes NeoLab, Heidelberg, Germany 
8 well chamber slides Ibidi, Martinsreid, Germany 
Lab Tek II chamber slides Nunc international, USA 
Tissue culture dishes Ø 100x20mm TPP, Trasadingen, Switzerland 
Tissue culture dishes Ø 150x20mm TPP, Trasadingen, Switzerland 
Tissue culture dishes Ø 35x10mm Becton Dickinson, Franklin Lakes, NJ, USA 
Tissue culture flasks 150 cm2 TPP, Trasadingen, Switzerland 
Tubes 15 and 50 mL TPP, Trasadingen, Switzerland 
Tubes 1.5 and 2 mL TPP, Trasadingen, Switzerland  
 
All other reagents were of analytical grade and are commercially available from Invitrogen, 
SIGMA or ROTH. 
 
3.2 Experimental procedures 
3.2.1 Animals 
C57BL/6 wild-type mice and Ripk3-deficient C57BL/6 mice were obtained from 
Charles River (Sulzfeld, Germany) and Genentech (Viswa Dixit) respectively. All mice were 
kept under normal housing conditions under a 12-h light and dark cycle. Water and standard 
chow (Ssniff, Soest, Germany) were available ad libitum for the complete duration of the 
study. Cages, bedding, nestles, food, and water were sterilized by autoclaving before use. 
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3.3 Blood collection 
3.3.1 Human blood sample collection 
All blood donors provided written informed consent forms approved by the local 
ethical committee for human neutrophil isolation. Blood samples from a healthy donor for 
most of the studies, as well as blood from CGD patients in some studies, were used. Whole 
blood was collected into heparin tubes from the facial vein and was processed for neutrophil 
isolation.  
3.3.2 Mouse blood sample collection  
Mouse blood samples were collected by retro-orbital bleeding technique, under 
isoflurane anesthesia, in microcentrifuge tubes containing heparin. Mice were carefully bled 
to harvest the maximum amount of peripheral blood.  
3.4 Human and mouse neutrophil isolation 
As mentioned above, whole blood from either mice or human subjects was collected 
into heparin tubes in a very careful manner to avoid the activation of neutrophils by physical 
means. The blood sample was mixed with 1,25% of high molecular weight dextran (molecular 
weight 450K-650K), and RBCs were allowed to settle at 4
0
C. The upper clear yellowish 
leucocyte-rich layer was separated and lysed for the remaining RBCs using hypnotic lysis 
(ddH2O) and tonicity was maintained by adding 0,15M KCl. Resultant leucocytes were 
enriched for neutrophils by gradient centrifugation with Biocoll solution (density of 0,177). 
As the neutrophils were very sensitive to the external stimuli, care was taken not to activate 
them by aggressive shaking and all the procedure were performed at 4
0
C. No glass material 
was used as neutrophils sticks to the glass surface. Once the pure neutrophils were isolated, 
suspended in plain RPMI media and then incubated at 37
0
C in CO2 incubator for 30 minutes. 
 
3.5 Induction of NETs 
Isolated mouse or human neutrophils were suspended (0.5x10
6
 or 5x10
6
) in 200µl to 
500µl plain RPMI. They were seeded into 8 well µ slides or 12-well plates (Ibidi, Martinsried, 
Germany) to settle for 30 min in a 5% carbon dioxide atmosphere at 37°C. These neutrophils 
were exposed to different doses of different cell death inhibitors Nec-1 (Enzo Life Sciences, 
Lörrach, Germany), Nec-1s (Biovision, Milpitas, CA), Ferrostatin (Calbiochem, Germany) , 
zVAD (Enzo Life Sciences, Lörrach, Germany), NSA (Millipore, Schwalbach, Germany), 
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PAD inhibitor-Cl-amidine (Merck Millipore,Germany) for 30 min pretreatment before adding 
stimulators of NETs.  
To induce NETs various stimuli were used. Neutrophils were incubated for 2-6 hours 
after stimulations with stimuli like PMA (Sigma–Aldrich, Steinheim, Germany), LPS 
(InvivoGen, San Diego, CA), TNF (Immunotools, Germany) or various crystals like CaOx 
(Alfa Aesar, Germany), MSU (Invivogen, Toulouse, France), CaP (Sigma life sciences, 
Germany), Cystine (Chem Cruz), CPPD (Invivogen, Toulouse, France), Cholesterol 
(Invivogen, Toulouse, France), alum (Invivogen, Toulouse, France), silica (Alfa Aesar, 
Germany), asbestos (SPI-CHEM), and TiO2 (Io-li-tec nanomaterials, Heilbronn, 
Germany).The NET soups were harvested for different biochemical assays, whereas the 
neutrophils in culture plates were preceded for different imaging approaches. 
 
3.6 Live cell SYTOX imaging  
In order to study the neutrophil cell death after different treatments and stimulations 
with different stimuli, 0.1 μM Sytox green dye (Life Technologies, Eugene, OR, USA) was 
added post stimulation. The cells were incubated in dark for 10min at RT to allow the cells to 
take up the dye. Sytox green is a DNA staining dye, which is a cell membrane impermeable 
dye. Thus, the cell death, which involves plasma membrane and the release of extracellular 
DNA, can be detected. Neutrophil cell death was detected by performing live cell imaging 
using Zeiss observer microscope.  
3.6.1 Quantification of Sytox+ dead cells  
Multiple images per stimulation group were taken to perform the quantitative analysis 
of Sytox+ dead cells. In the case of mouse neutrophils, the sytox+ cells were counted 
manually using the imageJ software. Total %cell death was compared within the different 
groups. Due to the higher cell number for human neutrophils, the mean green area/field was 
calculated using ImageJ software to indicate the cell death.  
 
3.7 Confocal imaging and immunostaining  
For Confocal imaging, neutrophils were fixed using 4% formaldehyde for 10 min at 
RT after removing the supernatant. The cells were washed with 1X PBS for 3 times and were 
stored in PBS at -20 °C. The cells prepared as described above, were incubated with the 
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following primary antibodies: antihistone IgG (clone BWA3, Immunomedics, Morris Plains, 
NJ, USA) Neutrophil elastase (Santa Cruz Biotechnology, Santa Cruz, CA), citH3 (Cell 
signaling, Danvers, MA) and TO-PROR-3 Iodide (Life Technologies) for 1 h in PBS or 
0.1% milk solution in room temperature. After washing, the sections were incubated with 
secondary antibodies guinea pig Alexa Fluor 488 (1:100, Invitrogen, Carlsbad, CA) or rabbit 
Cy3 (1:200, Jackson ImmunoResearch Laboratories, West Grove, PA) for 30 minutes at room 
temperature. Stainings were evaluated using confocal microscopy with LSM 510 microscope 
and LSM software (Carl Zeiss AG).  
For immunohistological studies, tophus containing air pouch skin sections from each 
mouse were fixed in formalin (10 % in PBS or Saline) overnight and processed using tissue 
processors (Leica) and paraffin blocks were prepared. 2µm thick paraffin-embedded sections 
were cut. De-paraffinization was carried out using xylene (3 * 5 min) followed by re-
hydration, which was carried out by incubating the sections in 100% absolute ethanol (3 * 3 
min), 95% ethanol (2 * 3 min) and 70% ethanol (1 * 3 min) followed by washing with PBS (2 
* 5 min). Blocking endogenous peroxidase was carried out by incubating sections in H2O2 and 
methanol mixture (20 ml of 30% H202 in 180ml of methanol) for 20 min in the dark followed 
by washing in PBS (2* 5min). For unmasking of antigen, sections were dipped in antigen 
unmasking solution (3 ml of antigen unmasking solution + 300 ml of distilled water) and 
cooked in the microwave for a total of 10 min (4*2.5 min, every 2.5 min water level was 
checked and made up to the initial levels with distilled water every time). After microwave 
cooking sections were cooled to room temperature for 20 min and washed with PBS. 
Blocking endogenous biotin was carried out by incubating sections with one drop of Avidin 
(Vector) for 15 min followed by incubation with Biotin (Vector) for further 15 min. After the 
incubation was over sections were washed with PBS (2* 5 min). 
For several antibodies, the immunofluorescent studies were performed on five 
micrometer-thick cryo/frozen kidney or bladder sections without fixation with 4% 
formaldehyde.  
Sections were incubated with different primary antibodies either for 1 hour at room 
temperature or overnight at 40C in a wet chamber followed by wash with PBS (2* 5 min). 
After washing sections were incubated with biotinylated secondary antibodies (1:300, dilution 
in PBS) for 30 min followed by a wash with PBS (2* 5 min). Substrate solution (ABC 
solution, Vector) was added and sections were incubated for 30 min at room temperature in a 
wet chamber followed by a wash with PBS (1* 5 min). Tris (1* 5 min) and sections were 
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stained for DAB followed by counterstaining with methyl green (Fluka). Then sections were 
washed with alcohol (96 %) to remove excess stain and xylene. Sections were dried and 
mounted with VectaMount (Vector). 
The primary antibodies used in the study are mentioned above. For each 
immunostaining, negative controls staining was performed by incubation with a respective 
isotype antibody instead of primary antibody. 
 
3.8 Transmission and scanning electron microscopy  
Primary neutrophils with/without different stimuli were fixed in 2.0 % 
paraformaldehyde/ 2.0 % glutaraldehyde, in 0.1 M sodium phosphate buffer, pH 7.4 for 24 
hours, followed by 3 washes x15 min in 0.1 M sodium phosphate buffer, pH 7.4 and distilled 
water.  For transmission EM kidneys were post-fixed, in phosphate cacodylate-buffered 2 % 
OsO4 for 1h, dehydrated in graded ethanols with a final dehydration in propylene oxide and 
embedded in Embed-812 (Electron Microscopy Sciences, Hatfield, PA). Ultrathin sections 
(~90-nm thick) were stained with uranyl acetate and Venable's lead citrate. Specimens were 
viewed with a Zeiss Libra 120 Transmission electron microscope.  
For scanning electron microscopy, kidney tissue was rinsed with PBS and postfixed 
with 1% aqueous osmium tetroxide for a total of 2.5 h. Subsequently, tissues were rinsed and 
dehydrated through a graded series of ethanol to absolute ethanol and critical point dried 
using liquid CO2. After mounting on stubs the specimens were sputter coated with a gold-
palladium alloy for 1.5 min. Images were viewed with a Hitachi 2600 electron microscope. 
 
3.9 Quantitative analysis of NETs and cell death 
3.9.1 Pico green assay 
The NETs include extracellular chromatin. The supernatant was harvested to quantify 
the DNA release from NET forming neutrophils post various NET inducing stimuli.  After 
removing floating free nuclei (centrifugation at 1500 rpm for 5 min), DNA release in 
supernatant was determined by adding 50 μL of Pico green dsDNA assay kit reagent (Life 
Technologies; 1:250 in TE buffer) to 50 μLof cell culture supernatant, and fluorescence was 
read after 5 min with an excitation and emission wave lengths of 485 and 535 nm.  
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3.9.2 Reactive oxygen species assay 
Primary neutrophils (0.5x10
6
 /well) were seeded in 96 well plates. The cells were pre-
incubated with DCFDA dye followed by the treatment with different cell death inhibitors and 
stimuli like PMA or MSU crystals for 2 hours. DCFDA is deacetylated by cellular esterases to 
a non-fluorescent compound, which is later oxidized by reactive oxygen species (ROS) into 
2’, 7’ –dichlorofluorescein (DCF) after diffusion in the cells. The amount of the fluorescent 
compound was measured using the photospectrometer at excitation and emission wave 
lengths of 485 and 535 nm.  
3.9.3 Lactate dehydrogenase cell death assay 
Primary neutrophils (0.5x10
6
 /well) were seeded in 96 well plates in plain RPMI 
medium. Post the treatment with different inhibitors and crystal stimulations for 2h, the 
supernatant was collected and transferred to a new 96 well plate. The cell-free supernatant 
was incubated with substrates of lactose dehydrogenase (LDH) cytotoxicity detection kit 
(Roche, Germany). LDH activity is higher in the case of cell death. During this assay, LDH 
activity is determined by a coupled enzymatic reaction between LDH and substrate dye. The 
absorbance of the dye was read at 492nm, which directly correlates, to the amount of LDH 
present in the supernatant.  
3.9.4 Cell viability assay 
To check the cell viability, cells were seeded (0.1x10
6
 /well) in 96 well plates. Post the 
treatment with different inhibitors and crystal stimulations for 24h, the 15µl 3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) dye (Sigma-alderich, 
Germany) was added to the wells. The yellow coloured MTT dye interacts with mitochondrial 
dehydrogenases of viable cells and produces purple coloured crystals soluble in acidified 
isopropanol. The absorbance was read at 570nm using photospectrometer. The absorbance 
was directly proportional to the number of viable cells in the well.  
3.10 Other In-vitro analysis 
3.10.1 Cell culture 
MTCs, human synovial fibroblasts (K4IM cells) and L929 cells were maintained in 
DMEM/F12 (GIBCO, Invitrogen, CA, USA) containing 10% fetal calf serum, 1% penicillin–
streptomycin. Human kidney cells (HK-2) were maintained in RPMI (GIBCO, Invitrogen, 
CA, USA) containing 10% fetal calf serum and 1% penicillin–streptomycin. MTCs are a cell 
line immortalized with SV-40 virus41, and K4IM cells are a cell line immortalized with SV-
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40 T large antigen42, 43. MTCs and K4IM cells were generously provided by EG Neilson 
and PJ Nelson, respectively. L929 cells and HK-2 cells were purchased from ATCC. Human 
renal progenitor cells were prepared from human kidney tissues using standard sieving 
technique through graded mesh screens (60, 80, 150 and 200 mesh)24. All cells were 
stimulated with different doses of crystals of CaOx (1–2 mm size; Alfa aesar, Germany), 
MSU (25–125 nm size; Invivogen, Germany), CPPD (25–125 nm size; Invivogen, Germany) 
and cystine (1–2 mm size; Sigma Aldrich, Germany) in different experiments. Cells were 
pretreated with necrostatin-1 (50 or 100 mM) or ZVAD-FMK (10 mM) or combination 30 
min before crystals stimulations whenever required. 
Primary tubular epithelial cells were isolated from the kidneys and were maintained in 
DMEM/F12 containing 10% fetal calf serum, 1% penicillin–streptomycin, 125 ng ml1 
prostaglandin E1 (Calbiochem, Germany), 25 ng ml1 EGF, 1.8 mgml1 l-thyroxine, 3.38 
ng ml1 hydrocortisone and 2.5 mg ml1 of insulin–transferrin—sodium selenite 
supplement (all from Sigma Aldrich, Germany unless mentioned). Cells were grown to 
confluence before use in experiments. Primary renal human progenitor cells were plated in 
EGM-MV (Lonza Ltd., Basel, Switzerland) with 20% FBS (Hyclone, Logan, Utah). 
Generation of clones was achieved by limiting dilution in 96-well plates and in four-chamber 
glass slides (VWR International, West Chester, Pennsylvania). All the cells were cultured in 
an incubator at 37
0
C, 5% CO2. CellTiter 96 non-radioactive cell proliferation assay (MTT) kit 
(Promega, Germany) was used to evaluate cell survival after 24 h following the 
manufacturer’s instructions. Results were expressed as a percentage of the vehicle control. 
 
3.10.2 Cell freezing and thawing 
At earlier passages, large amounts of cells were grown under standard culture 
conditions and were frozen for future use. Cells to be frozen were detached from the culture 
plates and were spun down under sterile conditions for 3 min at 1000 RPM. The cell pellet 
was maintained on ice and carefully re-suspended in cold freezing medium (90 % respective 
culture medium and 10 % DMSO) by pipetting the suspension repeatedly up and down. 1.5 
ml aliquots were quickly dispensed into freezing vials (4
0
C). The cells were slowly frozen at –
20
0
C for 1 h and then at –80
0
C overnight. The next day, all aliquots were transferred to liquid 
nitrogen. 
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In order to thaw cells, a frozen vial was removed from liquid nitrogen and put in a 
water bath at 37
0
C. The cells were then dispensed in 5 ml of warm complete growth medium 
and spun down at 1000 RPM for 5-7 min. Then the old medium was removed and the cells 
were re-suspended in fresh medium and transferred to new culture plate. The medium was 
changed once more after 24 h. 
3.10.3 Stimulation experiments 
For cell stimulation experiments, the cells were seeded at a density of 5X10
5
 cells/well 
in six-well plates in DMEM and grown overnight to the confluence. Cells were treated with 5 
µg/ml ultrapure LPS (InvivoGen, San Diego, CA) and incubated at 37
0
C, 5% CO2 for 0.5–18 
h. Total cell protein was extracted for western blot analysis and supernatants were collected 
for IL-6 or TNF-α ELISA. Nuclear proteins were isolated by using high-salt extraction. 
 
3.11 Protein isolation and western blotting 
Proteins from primary neutrophils from cell culture were extracted using RIPA buffer 
(Sigma, Germany) containing protease inhibitors (Roche, Germany). In brief, after neutrophil 
stimulations to induce NETosis, the supernatant was harvested carefully without disturbing 
the NETs on the surface. The cells were then lysed in the RIPA buffer containing protease 
inhibitors. The lysates were then maintained at constant agitation for two hours at 4
0
C. The 
samples were then centrifuged for 5 min at 5000 rpm at 4
0
C. Then the supernatant (proteins) 
was separated in a new tube and the pellet was discarded. Protein estimation was done using 
Barford´s assay. 
After determination of protein concentrations, 50µg of the protein was mixed with 5x 
SDS loading buffer (100 mM Tris-HCl, 4% SDS, 20% glycerol, and 0.2% bromophenol blue) 
for Western blot analysis. Samples were heated at 95°C for 5 min. Proteins were separated by 
SDS PAGE and then transferred to a polyvinylidene difluoride (PVDF) membrane. 
Nonspecific binding to the membrane was blocked for 1hr at room temperature with 5% milk 
in Tris-buffered saline buffer (20 mM Tris-HCl, 150 mM NaCl, and 0.1% Tween 20). The 
membranes were then incubated overnight at 4°C with primary antibodies.  After washing, the 
membrane was incubated with respective secondary antibodies in Tris buffered saline buffer. 
The signals were visualized by an enhanced chemiluminescence system (Amersham, 
Buckinghamshire, UK). 
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3.12 Cytokine ELISA 
All cytokine levels in supernatant collected from in-vitro cells stimulations were 
estimated using ELISA kits following the manufacturer’s instructions. In brief, The NUNC 
ELISA plate wells were captured overnight at 4°C with the capture antibody in coating buffer. 
Next day the plates were washed 3 times with the washing buffer as given in protocol for 3 
times and blocked with the blocking solution or assay diluent for 1 hour or as specified. Again 
the washings were repeated 3 times followed by addition of standards; samples and sample 
diluent (blank) into the wells of tap dried plate and incubated at RT for 2 hours. Washings 
followed this for 5 times or as specified. Then HRP/AP conjugated secondary antibody 
diluted in assay diluent was added. Incubate the plate as specified for the primary Ab. The 
wells were washed again for 5-7 times or as specified and incubated with the 100 μl of 
substrate A and B (1:1 mixture) for 25-30 min in the dark to develop colour. The reaction was 
stopped by addition of 100 μl 1 M H2SO4. The reading of the absorbance was taken at 450 
nm and the reference wavelength was 620 nm using a spectrophotometer (TECAN-Genios 
Plus). 
 
3.13 Flow cytometry for neutrophil population 
Flow cytometric analysis of neutrophils after neutrophil isolation was performed on a 
FACS Calibur flow cytometer (BD) as described. Every isolate was incubated with binding 
buffer containing either anti-human CD15 (BD bioscience), CD11B (BD bioscience) and 
CD66b (Biolegend) for 45 min at 40C in the dark were used to detect neutrophils.  
 
3.14 Statistical analysis 
Data are presented as mean ±SEM. For multiple comparisons of groups one-way 
ANOVA was used followed by post-hoc Bonferroni`s test, using SigmaStat (Jandel Scientific, 
Erkarath, Germany). Paired Student`s t-test was used for the comparison of single groups. A 
value of p < 0.05 was considered to indicate statistical significance. 
 
 
Results   41 
 
4. Results 
4.1 Part I: Crystals induce neutrophil cell death and NET formation 
Crystals are deposits of various sizes and shapes composed of atoms, ions or 
biomolecules. Crystal formation under physiological conditions can cause tissue injury and 
inflammation in diseases like gouty arthritis, pulmonary silicosis or asbestosis, cholesterol 
crystals driving atherogenesis and in oxalate, cystine or urate nephropathy. These crystals are 
known to induce direct cytotoxicity during injury. However, the mechanisms are not yet fully 
known. To understand the role of various crystals on cytotoxicity, we first screened a wide 
range of crystals like CaOx, MSU, CPPD, CaP, cholesterol, myoglobin, asbestos, silica, alum 
crystals and titanium dioxide nanoparticles. To understand the shape and size of these 
crystals, we performed transmission electron microscopy (figure 4).  
 
 
Figure 4: Transmission electron microscopy images of different crystals. Crystals were fixed with EM 
fixative and were subjected to perform TEM imaging. (Scale bar: 0.5 μm). CaOX: calcium oxalate, MSU: 
monosodium urate, CPPD: calcium pyrophosphate dihidrate, TiO2: Titanium dioxide.  
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Figure 5: Flow cytometry of isolated human neutrophils. Human neutrophils were isolated using Ficoll. 
Density gradient and the obtained neutrophil pellet was stained for the surface markers, CD15, CD11b and 
CD66b. More than 95% purity was obtained for this isolation method.  
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Figure 6:  Various crystals induce necrotic cell death of neutrophils. Human primary neutrophils were 
exposed to different concentrations of CaOx, MSU, Calcium phosphate, CPPD, cysteine, Myoglobin and 
cholesterol crystals (500µg/ml). Cell death was assessed by LDH assay 2h later. Data are expressed as mean cell 
viability±s.e.m. of three independent experiments. Data were analyzed using Student’s t-test. **P<0.01 and 
***P<0.001 versus respective medium control. CaOX: calcium oxalate, MSU: monosodium urate, CPPD: 
calcium pyrophosphate dihidrate, TiO2: Titanium dioxide. 
 
It is known that crystals also exert direct cytotoxic effects leading to necrotic rather 
than apoptotic cell death. Since neutrophils are the first responder cells to reach the site of 
injury and infection, we were interested in understanding the interactions between crystals and 
neutrophils. Neutrophils were isolated from human peripheral blood. More than 95% pure 
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neutrophil population was obtained using Ficoll density gradient centrifugation (figure 5). 
Isolated neutrophils were then exposed to various crystals for 2 hours at 37
o
C. The 
supernatants were harvested and tested for LDH release. Almost all crystals led to necrotic 
cell death of neutrophils (figure 6).  
To understand the morphology of neutrophil cell death upon crystal stimulation, we 
exposed primary neutrophils to various crystals for 2 hours and processed them for scanning 
electron microscopy and transmission electron microscopy. The SEM images (figure 7) 
showed that upon crystal stimulation, neutrophils undergo cell death that resembles NET 
formation and we observed NET-crystal aggregates upon stimulation of most of the crystals. 
Since NET formation can occur with or without cell death, we were interested in investigating 
the morphology of these crystal-induced NET like structures.  
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Figure 7: SEM images of neutrophils cell death and NET formation. Primary human neutrophils were fixed with 
EM fixative after 2h of various crystal stimulations. Images from each group are represented in both higher and 
lower magnifications. CaOX: calcium oxalate, MSU: monosodium urate, CPPD: calcium pyrophosphate 
dihidrate, TiO2: Titanium dioxide. 
For TEM, the primary neutrophils were stimulated with different crystals for 2 hours 
at 37
o
C in 1.5 ml eppendorf tubes and were fixed with EM fixative for 10 min at RT. The 
samples were processed further for TEM. We saw that upon stimulation with different 
crystals, most of the neutrophils appeared necrotic with plasma membrane ruptures. The 
nuclear material looked less condensed, leading to the assumption of chromatin being 
expelled during cell death. The TEM images (figure 8) showed that indeed the plasma 
membrane rupture was associated with neutrophil cell death upon crystal exposure, indicating 
NET related necrotic form of cell death. Furthermore, to study the crystal-NET aggregates, 
we performed immunofluorescence analysis of neutrophils stimulated with different crystals. 
Neutrophils were fixed with 4% paraformaldehyde post crystal stimulation. The cells were 
stained for NET markers: citH3, neutrophil elastase and DNA (figure 9). We observed that 
most of the crystals induced strong crystal-NET aggregates. These aggregates were not 
present, when neutrophils were treated with histones or myoglobin solutions. Thus, NET 
aggregates looked a very specific feature only associated with neutrophil-micro/nano particle 
interactions.   
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Figure 8:  TEM images of neutrophil cell death upon crystal stimulation.  Primary human neutrophils were 
fixed with EM fixative after 2h of various crystal stimulations.  The neutrophil cell death appears to be 
associated with plasma membrane rupture and chromatin decondensation (Scale bar: 5µm) CaOX: calcium 
oxalate, MSU: monosodium urate, CPPD: calcium pyrophosphate dihidrate. 
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Figure 9:  Immunofluorescence imaging of NET-crystal aggregates.  Post 2h stimulation of human primary 
neutrophils with different crystals, cells were fixed and were stained for NET markers. (DNA: Blue, Neutrophil 
elastase: Green, citrunilated histone: Red). CaOX: calcium oxalate, MSU: monosodium urate, CaP: calcium 
phosphate, CPPD: calcium pyrophosphate dihidrate, TiO2: Titanium dioxide. 
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Figure 10: Human neutrophils were stimulated with either PMA or MSU for different time (0-3h). Release of 
IL-1β (A) and TNF-α (B) release in the supernatant was detected by ELISA. *p<0.05, +p<0.05, *** p<0.01, 
+++p<0.001 versus medium control.  PMA: phorbol myristate acetate, MSU: monosodium urate.  
 
4.2 Part II: Molecular mechanisms of MSU & PMA-induced NET formation & cell 
death  
We specifically studied neutrophils since neutrophils are the first responder cells that 
reach at the site of crystal injury. We were particularly interested in dissecting the molecular 
mechanisms involved in MSU crystal-induced neutrophil NET formation and neutrophil cell 
death.  
4.2.1 PMA and MSU induce release of IL-1β but not TNF-α from neutrophils 
To analyze the chemokines and cytokines released during the PMA and MSU-induced 
NET formation as well as cell death, the supernatant of neutrophils was collected in a time-
dependent manner (1-3 hours) after stimulations with PMA (25nM) and MSU crystals 
(20pg/cell). We observed that IL-1B was released in a time-dependent manner upon both 
PMA and MSU stimulations (figure 10A) for neutrophils isolated from healthy individuals. 
Whereas the cytokine TNFa was not released in a time-dependent manner during this process 
(figure 10 B).  
4.2.2 Anakinra, etanercept, anti-TLR4, FAS deficiency do not block PMA & MSU induced 
NETs & cell death 
To further check if the release of IL-1 or TNFa plays a role in the process of NET 
formation or cell death upon PMA and MSU crystal stimulations, the healthy control human 
neutrophils were pre-treated with the  IL-1 receptor antagonist anakinra (dose) and TNFa 
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antagonist Etanercept followed by PMA or MSU crystal stimulations for 2 hours. The 
supernatant was collected and the DNA release into supernatant was checked using the Pico 
green assay to measure the cell death as well as NET release. Our data suggests that both the 
pre-treatment with neither anakinra nor etanercept had any effect on the DNA release upon 
PMA and MSU crystal stimulations (figure 11A). In fact, pre-treatment with TLR4 antibody 
did not affect the DNA release ruling out the role of TLR4 in this process (figure 11B). 
Moreover, the neutrophils isolated from Fas
lpr
 mice were able to form NETs and undergo cell 
death upon PMA and MSU which showed that the lack of Fas did not affect the neutrophil 
NETs and cell death (figure 11C).  
4.2.3 Screening of different cell death inhibitors for PMA induced NETs and cell death  
According to our hypothesis, we wanted to check if different cell death pathways are involved 
in the process of NETosis. We screened the chemical inhibitors of different cell death 
signaling pathways like pan-caspase inhibitor zVAD-FMK (10µM) for apoptosis, Stabilizer 
of RIPK1 necrostatin-1 and more specific necroptosis inhibitor necrostatin-1s for necroptosis 
or ferrostatin for the pathway of Ferroptosis (figure 12). The isolated human neutrophils from 
healthy controls were pre-treated with this cell death inhibitor for 30 min prior to stimulations 
with 25nM PMA, a standard NET and cell death inducer for 2h. The supernatant was 
harvested and the DNA release was measured using the Pico green assay. As shown in figure 
13, neither zVAD-FMK nor ferrostatin-1 (Fer-1) had an effect, excluding caspase-mediated 
extrinsic apoptosis or pyroptosis, or ferroptosis respectively. In contrast, first-generation 
necrostatin Nec-1 and Nec-1s decreased overall cell death and NET formation as assessed by 
the release of DNA using Pico green dye. This indicated that RIP1-RIP3- 
MLKL mediated necroptosis cascade might be involved in the the process of neutrophil cell 
death. 
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Figure 11: DNA release into the supernatant 2 hours after stimulation with either PMA or MSU crystals was 
quantified by PicoGreen. Human neutrophils were prestimulated with either Anakinra (IL-1R1 antagonist) 
(100ng/ml) or Etanercept (TNF-α antagonist) (100ng/ml) (D), Isotype IgG control antibody or anti-TLR4 
neutralizing antibody (100ng/ml) (E) before adding either PMA or MSU crystals. F: Neutrophils were isolated 
from wild type and C57-BL6lpr mice, and were stimulated with either PMA or NSA. DNA release into the 
supernatant 2 hours after stimulation was quantified by PicoGreen. Data are means ± standard error of mean 
from three independent experiments. *p<0.05, N.S: not significant versus medium control.  PMA: phorbol 
myristate acetate, MSU: monosodium urate.  
 
4.2.4 Nec-1 and NSA inhibit overall PMA-induced NET formation and cell death  
To address the involvement of the necroptosis cascade in PMA-induced NETs and 
neutrophil cell death, neutrophils isolated from healthy individuals were pre-treated with 
different doses of Nec-1 and Nec-1s. Nec-1 inhibits necroptosis via modulating RIPK1 and 
preventing downstream events of RIPK3 and MLKL phosphorylation and necrosome 
formation. Furthermore, we also pre-treated neutrophils with different doses of human species 
specific MLKL inhibitor necrosulfanamide (NSA). 
n.s. 
n.s. 
n.s. 
n.s. 
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Figure 12: Human neutrophils were exposed to PMA in the presence of several cell death inhibitors Nec-1 (50 
μM), Nec-1s (50 μM), zVAD-FMK (10 μM), and Ferrostatin-1 (Fer-1, 2 μM) as indicated. DNA release into the 
supernatant was quantified by PicoGreen detection after 2 h as a marker of NET-related chromatin release. 
*p<0.05 versus PMA treatment. PMA: phorbol myristate acetate, Nec-1: necrostatin-1, zVAD: pan-caspase 
inhibitor, Ferro: ferrostatin-1.  
 
MLKL is a downstream protein of the necrosome complex. We observed that 
treatment with first-generation Nec)-1, Nec-1s, and the NSA decreased overall cell death and 
NET formation as assessed by nuclear SYTOX uptake, the release of DNA using Pico green 
dye, and chromatin release to induce NET structures (figures 13-16). Ultrastructurally, Nec-1 
or NSA inhibited the rupture of nuclear and plasma membranes of neutrophils upon PMA 
stimulation (figure 17).  
 
 
 
 
 
 
Figure 13: DNA release into the supernatant after exposure to PMA was quantified by PicoGreen detection after 
2h as a marker of NET-related chromatin release. All data are expressed as means ± SE of the mean from three 
independent experiments. *p < 0.05  versus PMA. PMA: phorbol myristate acetate, nec-1: necrostatin-1, NSA: 
necrosulfanamide.  
.  
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Figure 14: SYTOX green immunofluorescence 2h after 25nm PMA exposure to human neutrophils in after 
pretreatment with either necrostatin-1 (Nec-1) or necrosulfonamide (NSA) as indicated. SYTOX green detects 
permeability of plasma and nuclear membranes. Representative images are shown at an original magnification of 
200x. PMA: phorbol myristate acetate, nec-1: necrostatin-1, NSA: necrosulfanamide.  
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Figure 15: A quantitative analysis of Sytox+ve dead cells, NETs after 2h of PMA exposure  is shown as means 
± SE of the mean from three independent experiments. All data are expressed as means ± SE of the mean from 
three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 versus PMA. PMA: phorbol myristate 
acetate, nec-1: necrostatin-1, NSA: necrosulfanamide.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Confocal microscopy of human neutrophils post stimulating with 25nm PMA for 2h after 
pretreatment with either necrostatin-1 (Nec-1) or necrosulfonamide (NSA) as indicated stained with FITC-
antihistones (green) and TOPRO (blue) to detect histones and DNA in extracellular traps. Representative images 
are shown at an original magnification of 400x. PMA: phorbol myristate acetate, nec-1: necrostatin-1, NSA: 
necrosulfanamide.  
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Figure 17: Transmission electron microscopy images of human neutrophils exposed to PMA in the presence or 
absence of necrostatin-1 (Nec-1) or NSA (scale bar: 5 μm). PMA: phorbol myristate acetate, nec-1: necrostatin-
1, NSA: necrosulfanamide.  
 
4.2.5 RIPK3 and p-MLKL is upregulated during PMA induced cell death and NETs  
 
RIPK3 and MLKL proteins are central players of the necrosome complex that initiate 
and carry out necroptosis. During activation of this pathway, RIPK3 is upregulated and 
eventually phosphorylated. RIPK3 further phosphorylates the downstream MLKL protein. 
Phosphorylation of MLKL is a crucial event of the necroptosis cascade. Since RIPK3 is 
known to be involved in other signaling pathways, phosphorylation of MLKL is considered to 
be the best hallmark of necroptosis on-set. We found that both RIPK3 and phosphorylation of 
MLKL are upregulated in a time-dependent manner (0-3h) during PMA induced NET 
formation and neutrophil cell death (figure 18).  
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Overall, the data indicate that PMA, which is a very common stimulous for NET 
induction is activating the RIPK1-RIPK3-MLKL mediated necroptosis, cell death cascade. 
This is followed by plasma membrane rupture and release of the NETs in extracellular space. 
 
A 
 
 
 
B       C 
 
 
      C 
 
 
 
 
 
Figure 18: Western blot for RIPK3 and phosphorylated MLKL at different time points after PMA stimulation of 
human neutrophils. β-Actin serves as loading control (n=3). B), C) Quantitative analysis of Western blots at 
different time points for RIPK3 and P-MLKL after PMA stimulation of human neutrophils. ** p<0.01, *** 
p<0.001 versus baseline. PMA: phorbol myristate acetate, Ripk3: receptor interacting kinase 3, p-MLKL: 
phosphor mixed lineage kinase like.  
4.2.6 Nec-1 and NSA inhibit both MSU-induced NET formation and cell death 
PMA is a commonly used NET inducer in-vitro. However, it is not a physiologically 
relevant stimulous that is associated with infectious or inflammatory diseases, in-vivo. To 
understand the involvement of necroptosis in NET related neutrophil cell death, we focused 
on another stimulous MSU crystals, associated with the pathophysiology of gout. MSU 
crystals trigger NET formation, which first drives massive inflammation and subsequently 
fosters the resolution of inflammation, explaining both gouty arthritis and tophus related 
immune energy. We exposed human neutrophils isolated from healthy individuals to MSU 
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crystals for 2h in-vitro. MSU crystals are known to form NETs. We observed that pre-
treatment with different doses of Nec-1 and NSA followed by MSU crystal stimulations 
decreased overall cell death and NET formation as assessed by nuclear SYTOX uptake, the 
release of DNA using Pico green dye, and chromatin release to induce NET structures (figures 
19-21).  
Figure 19: SYTOX green immunofluorescence 2h after 20pg/cell MSU exposure to human neutrophils in after 
pretreatment with either necrostatin-1 (Nec-1) or necrosulfonamide (NSA) as indicated. SYTOX green detects 
permeability of plasma and nuclear membranes. Representative images are shown at an original magnification of 
200x.  
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Figure 20:  A) A quantitative analysis of Sytox+ve dead cells, NETs is shown as means ± SE of the mean from 
three independent experiments. B) DNA release into the supernatant after exposure to MSU crystals was 
quantified by PicoGreen detection after 2h as a marker of NET-related chromatin release. All data are expressed 
as means ± SE of the mean from three independent experiments. *p < 0.05,  ***p < 0.001 versus MSU. MSU: 
monosodium urate, nec-1: necrostatin-1, NSA: necrosulfanamide.  
 
 
 
 
 
 
 
 
 
Figure 21: Confocal microscopy of human neutrophils post stimulating with 20pg/cell MSU crystals for 2h after 
pretreatment with either necrostatin-1 (Nec-1) or necrosulfonamide (NSA) as indicated stained with FITC-
antihistones (green) and TOPRO (blue) to detect histones and DNA in extracellular traps. Representative images 
are shown at an original magnification of 400x. MSU: monosodium urate, nec-1: necrostatin-1, NSA: 
necrosulfanamide.  
 
Moreover, Nec-1 or NSA inhibited the rupture of nuclear and plasma membranes of 
neutrophils upon PMA stimulation as observed in their ultrastructural appearances using TEM 
(figure 22). 
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Figure 22: Transmission electron microscopy images of human neutrophils exposed to MSU in the presence or 
absence of necrostatin-1 (Nec-1) or NSA (scale bar: 5 μm). . MSU: monosodium urate, nec-1: necrostatin-1, 
NSA: necrosulfanamide.  
 
4.2.7 p-MLKL is upregulated in MSU crystal-induced NET formation and cell death 
 
In addition to the pharmacological inhibition of the RIP1-RIP3-MLKL mediated 
necroptosis pathway in MSU crystal-treated human neutrophils, we checked if the necroptosis 
cascade was activated during the MSU crystal-induced NET formation and neutrophil cell 
death. Human neutrophils isolated from the healthy controls were subjected to MSU crystals 
(20pg/cell) exposure for 0-2h. The cells were harvested and the expression of phosphor-
MLKL was checked. As mentioned earlier, phosphorylation of MLKL protein is considered 
to be the most important and exclusive event of the onset of necroptosis cascade. We 
observed that indeed, the MLKL phosphorylation increased in a time-dependent manner upon 
MSU crystal stimulations, confirming the activation of necroptosis pathway during MSU 
crystal-induced neutrophil NET formation and cell death (figure 23).   
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Taken together, our data show the importance of necroptosis pathway during MSU crystal-
induced neutrophil cell death. This to our knowledge is the first evidence of the involvement 
of necroptosis during the event of NETosis.  
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Figure 23: (A) Phospho-MLKL western blot after MSU stimulation of human neutrophils. (B) Phospho-MLKL 
quantification after MSU stimulation of human neutrophils. β-actin was used as loading control. (n=3). *p<0.05, 
** p<0.01, *** p<0.001 versus baseline. . MSU: monosodium urate, p-MLKL: phosphor mixed lineage kinase 
like. 
 
4.2.8  ROS production is upstream of p-MLKL in PMA and MSU-induced NETs and cell 
death  
Generation of ROS is one of the key features of the NET formation event. We were 
further interested in checking if ROS are generated before or after the activation of 
necroptosis upon PMA or MSU crystal-induced NET formation and neutrophil cell death. We 
pre-treated the human neutrophils with Nec-1 or NSA before PMA or MSU crystal 
stimulations for 2h. After collecting the supernatant, we measured the quantity of ROS in the 
supernatant by using DCFDA dye (figure 24A and 24B). We observed no significant 
difference in ROS generation upon Nec-1 and NSA treatment suggesting that ROS might be 
produced upstream of the RIP1-RIP3-MLKL mediated cell death upon PMA and MSU 
stimulations. Moreover, we observed that MLKL phosphorylation was abrogated in 
neutrophils of patients with CGD upon PMA stimulation (figure 25). All in all, our 
experiments indicate the possibility of ROS being generated upstream of necroptosis.  
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Figure 24: Human neutrophils were pre-stimulated with either Nec-1 or NSA before adding PMA (A) or MSU 
(B). ROS were quantified using DCFDA dye. H2O2 was used as a positive control. Data are means ± standard 
error of mean. *p<0.05, **p<0.01, *** p<0.01 versus medium control. 
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Figure 25: Representative western blot for phosphorylated MLKL, totals MLKL (A) and quantification (B) at 
different time points after PMA stimulation. The experiment was performed in neutrophils isolated from 2 
healthy control or 2 chronic granulomatous disease (CGD) patients with NADPH-oxidase-deficiency (n=2 in 
each group). β-actin was used as loading control. *p<0.05, **p<0.01, *** p<0.01 versus medium control. 
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4.2.9 Ripk3-/- neutrophils do not undergo NET formation & cell death upon different 
stimuli  
To understand the functional role of necroptosis during the NET formation and 
neutrophil cell death events, we switched to mouse neutrophils as our model system to take 
advantages from molecular and genetic tools developed over the last decade. We isolated 
neutrophils from peripheral blood collected from Ripk3+/+ and Ripk3−/− mice and 
performed the in-vitro NETosis experiments like human neutrophils. Ripk3−/− mice are 
viable and physiologically normal. We exposed neutrophils from Ripk3+/+ and Ripk3−/− 
mice to different stimuli like MSU crystals, LPS and PMA for 2h like human neutrophils to 
induce NET formation and cell death. Considering the fact that mice neutrophils might take 
longer time to undergo NET formation and cell death, we also performed MSU crystals, LPS 
and PMA stimulations for 6h time point. We found that for both the time points, the Ripk3−/− 
neutrophils lacked the Sytox uptake upon the MSU, LPS and PMA stimulations. Overall 
neutrophil cell death decreased significantly compared to control Ripk3+/+ mice (figure 26, 
figure 27). The total number of NETs formed in Ripk3−/− mice was significantly decreased 
(figure 28, figure 29). Furthermore, through confocal imaging we observed that while the 
Ripk3+/+ neutrophils formed spectacular NETs made up of DNA (blue) and histones (green) 
decorated with neutrophil elastase (red), the Ripk3+/+ neutrophils failed to make these NETs 
(figure 30). 
Together, the in-vitro studies with mice neutrophils showed that RIPK3 is a central protein 
involved in PMA or MSU-induced NET formation. This observation is in line with our results 
with the treatment with pharmacological antagonists in human neutrophils.  
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Figure 26:  Neutrophils were isolated from the blood of WT and Ripk3- deficient mice and exposed to MSU 
crystal, LPS, and PMA for 6h. Sytox green was used to identify dying cells in culture. Representative images are 
shown at an original magnification of 200x. 
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Figure 27: Neutrophils were isolated from the blood of WT and Ripk3- deficient mice and exposed to MSU 
crystal, LPS, and PMA for 2h. Sytox green was used to identify dying cells in culture. Representative images are 
shown at an original magnification of 200x 
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Figure 28: A quantitative analysis of number of NETs MSU crystals (20pg/cell) LPS (100nM) and PMA 
(25nM) stimulations for A)6h and B) for 2h is shown as means ± SE of the mean from three independent 
experiments. *p<0.05, **p<0.01 versus medium control, t-test. N.S: not significant. 
 
 
 
 
 
 
 
 
Figure 29: A quantitative analysis of Sytox+ dead cells upon MSU crystals (20pg/cell) LPS(100nM) and 
PMA(25nM) stimulations for 2h is shown as means ± SE of the mean from three independent experiments. 
*p<0.05, **p<0.01 versus medium control, t-test. N.S: not significant 
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Figure 30:  Neutrophils were isolated from the blood of wild type and Ripk3-deficient mice and exposed to 
MSU, LPS, and PMA for 6hrs. A: Confocal microscopy for these cells stained with FITC-anti-histones (green) 
and TOPRO (blue) to identify NETs. Representative images are shown at an original magnification of 400x 
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4.3 Part III: Crystal-induced necroptosis in non-immune cells  
4.3.1 Crystal cytotoxicity involves necroptosis of non-immune cells 
The involvement of necroptosis cascade upon MSU crystal stimulations in neutrophils 
led us to our next interest of understanding the crystal induced non-immune cell death. What 
is the mode of crystal-induced non-immune cell death? To address this question we first 
studied the cytotoxic effects of calcium oxalate (CaOx), monosodium urate (MSU), calcium 
pyrophosphate dehydrate (CPPD) and cystine crystals on kidney epithelial cells in vitro. 
Transmission electron microscopy images and rhodamine-sytox stains to identify living and 
dead cells, respectively, showed that kidney tubular epithelial cells die by primary necrosis 
after crystal exposure (figure 31).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: TEM images show that these crystals induce necrosis of tubular epithelial cells as indicated by 
ruptured plasma membranes (middle, 2,000), scale bar, 2 mm. The images on the right show the same 
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rhodamine-labelled monolayers (red) 24 h later. When Sytox green is added to the medium cells with permeable 
plasma membranes turn green indicating cell death (x 200), scale bar, 40 mm. 
 
A       B 
 
 
 
 
 
 
 
 
Figure 32: (A): Mouse tubular epithelial cell viability on crystal exposure by 3-(4,5- dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay with and without the pan-caspase inhibitor ZVAD–FMK–FMK. All data are 
s.e.m.±means of at least three independent experiments. CaOx, MSU, CPPD, NS, not significant. *P< 0.05 
versus medium control, ***P< 0.001 versus respective control. (B).  Mouse tubular epithelial cells were 
pretreated with zVAD-FMK (10µM) and exposed to calcium oxalate (CaOx) crystals (1000µg/ml). Cell viability 
was determined by MTT assay. 
 
We found that different crystal induced cytotoxicity was not affected by pan-caspase 
inhibition (figure 32A and 32B). Having excluded the contribution of caspase-dependent 
forms of cell death, we focussed on necroptosis, a known regulated form of necrosis of non-
immune cells. The RIPK1 stabilisator necrostatin-1 partially (MSU, CPPD and cystine) or 
entirely (CaOx) prevented crystal-induced tubular epithelial cell death also in the absence of 
ZVAD–FMK (figure 33 and figure 34) suggesting a role for RIPK1 independent of caspases. 
When crystals were replaced by recombinant TNF- as a stimulus, necrostatin-1 had the same 
effect. However, the TNF- blocker etanercept had no protective effect on crystal-induced 
necroptosis (figure 35). This showed that TNF- does not mediate the crystal induced 
necroptosis in tubular epithelial cells.  
We further validated our finding in different cell types. We found that necrostatin-1 
also suppressed crystal cytotoxicity in L929 cells, primary human synovial fibroblasts, 
primary renal progenitor cells and HK-2 cells in a dose dependent manner (figures 36-39). 
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Figure 33: Mouse tubular epithelial cells were exposed to different concentrations of CaOx, MSU, CPPD or 
cystine crystals as indicated in the presence or absence of necrostatin (Nec)-1 (100 mM) together with the pan-
caspase inhibitor ZVAD–FMK–FMK posed to recombinant TNF-α (300ng/ml) as well as crystals of calcium 
oxalate (CaOx) (1000µg/ml), monosodium urate (MSU) (500µg/ml), calcium pyrophosphate dehydrate (CPPD) 
(500µg/ml) and cystine (500µg/ml). Cell viability was determined by MTT assay 24h later. Data are expressed 
as mean c(10 mM). Cell viability was assessed by MTT assay 24 h later. Data are expressed as mean cell 
viability±s.e.m. of three independent experiments. Baseline viability is set as 100%. Data were analysed using 
Student’s t-test. *Po0.05, **Po0.01 and ***Po0.001 versus respective medium control. NS, not significant. 
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) 
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Figure 34: Mouse tubular epithelial cells were pretreated with ZVAD-FMK (10µM), necrostatin (Nec)-1 
(100µM) or combination and ex ell viability ± SEM of three independent experiments. Baseline viability is set as 
100%. ** p<0.01, *** p<0.001 versus medium control. N.S. not significant.  
 
 
 
 
 
 
Figure 35: Crystal induced necroptosis does not involve TNF-α. Tubular epithelial cells were pretreated with 
etanercept (100mg/ml) and exposed to crystals of calcium oxalate (CaOx) (1000μg/ml), monosodium urate 
(MSU) (500μg/ml), calcium pyrophosphate dehydrate (CPPD) (500μg/ml), and cystine (500μg/ml). Cell 
viability was determined by MTT assay 24h later. Data are expressed as mean cell viability ± SEM of three 
independent experiments. Baseline viability is set as 100%. Data was analyzed using student’s t test. N.S. = not 
significant. 
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Figure 36: Crystals induce necroptosis in human synovial fibroblasts. Human synovial fibroblasts cells were 
exposed to crystals of calcium oxalate (CaOx), monosodium urate (MSU), calcium pyrophosphate dehydrate 
(CPPD) and cystine at different concentrations as indicated in the presence or absence of ZVAD-FMK-FMK 
(10μM) and necrostatin (Nec)-1 (100μM). Cell viability was determined by MTT assay 24h later. Data are 
expressed as mean cell viability ± SEM of three independent experiments. Baseline viability is set as 100%. Data 
was analyzed using student’s t test. * p<0.05, ** p<0.01, *** p<0.001 either versus vehicle control. 
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Figure 37: Crystals induce necroptosis in L929. L929 cells were exposed to crystals of calcium oxalate (CaOx), 
monosodium urate (MSU), calcium pyrophosphate dehydrate (CPPD) and cystine at different concentrations as 
indicated in the presence or absence of ZVAD-FMK-FMK (10μM) and necrostatin (Nec)-1 (100μM). Cell 
viability was determined by MTT assay 24h later. Data are expressed as mean cell viability ± SEM of three 
independent experiments. Baseline viability is set as 100%. Data was analyzed using student’s t-test. * p<0.05, 
** p<0.01, *** p<0.001 either versus vehicle control. 
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Figure 38: Crystals induce necroptosis in HK-2 cells. HK-2 cells were exposed to crystals of calcium oxalate 
(CaOx), monosodium urate (MSU), calcium pyrophosphate dehydrate (CPPD) and cystine at different 
concentrations as indicated in the presence or absence of ZVAD-FMK-FMK (10μM) and necrostatin (Nec)-1 
(100μM). Cell viability was determined by MTT assay 24h later. Data are expressed as mean cell viability ± 
SEM of three independent experiments. Baseline viability is set as 100%. Data was analyzed using student’s t 
test. * p<0.05, ** p<0.01, *** p<0.001 either versus vehicle control. 
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Figure 39: Crystal-induced necroptosis in human renal progenitor cells. Primary human renal progenitor cells 
were exposed to calcium oxalate (CaOx), monosodium urate (MSU), calcium pyrophosphate dehydrate (CPPD) 
and cystine at different concentrations as indicated in the presence or absence of ZVAD-FMKFMK (10μM) and 
necrostatin (Nec)-1 (100μM). Cell viability was determined by MTT assay 24h later. Data are expressed as 
percentage cell viability ± SEM of three independent experiments. Baseline viability is set as 100%. Data was 
analyzed using student’s t-test. * p<0.05, ** p<0.01, *** p<0.001 all versus vehicle control. 
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5. Discussion 
Various crystallopathies share certain common pathomechanisms, i.e. mechanical 
obstruction due to crystal deposits, cytotoxicity of cells that interact with crystals, and crystal 
induced inflammatory responses and activation of immune system. Various examples of 
crystallopathies include kidney stones that are formed as a result of hyperoxaluria or 
hypercalcuria leading to nephrocalcinosis.  In the urinary tract, crystallization usually starts in 
the renal tubules where supersaturation is a consequence of stepwise concentrating the 
glomerular filtrate and of the active secretion of calcium, uric acid, oxalate, phosphate or drug 
metabolites (Table 1)
136,137
 and this eventually hinder normal kidney functions. Furthermore, 
crystal masses may also cause vascular obstruction but through mechanisms other than stone 
formation. For example, atherosclerosis is a consequence of an accumulation of cholesterol 
crystals in the tunica intima of the arteria wall, the atheroma 
138
. In gouty arthritis, non- 
aggregating crystal masses of MSU form creamy tophi in subcutaneous layer of skin. Particles 
like silica and asbestos are known to induce silicosis and asbestosis, diseases associated with 
lung inflammation.  
Crystals induce direct inflammation, cytotoxicity and inflammation-driven necrosis, an 
auto-amplifying process referred to as “necroinflammation”.Upon interactions with crystals, 
cells experience significant cell stress, actin depolymerization, ROS production, and enhanced 
autophagy and cell death 
139
 In various crystallopathies, associated crystals act as DAMPs that 
activate the innate immune system.. A wide range of sterile particulates like crystals formed 
as a result of aberrant metabolism (calcium oxalate, monosodium urate, calcium 
pyrophosphate dehydrate, cystine, adenine, cholesterol etc.), external toxins (asbestos, silica), 
ischemia-reperfusion injury, and chemotherapy or irradiation to target depletion of specific 
cell population can elicit  inflammation
140
 
141
.  
Neutrophils are the first immune responder cells which are largely recruited at the site 
of injury caused by various crystals. Our data suggest that beyond their capacity to trigger 
inflammation, crystals of calcium oxalate, MSU, calcium phosphate. CPPD, cystine, 
cholesterol, silica, asbestos and different sizes of titanium dioxide nanoparticles induce direct 
cytotoxic effects in neutrophils. We observed that upon exposure to a large variety of crystals, 
primary human neutrophils undergo cell death in vitro. From various imaging approaches 
using TEM, SEM and confocal microscopy methods, we observed that the neutrophils often 
make crystal-NET aggregates. Thus, upon different crystal stimulation, neutrophils often form 
NETs which are associated with neutrophil cell death named NETosis. 
Discussion  77 
 
Cell death categories are no longer defined by morphological features but by the 
executing biochemical pathway, vice versa, the involved route of cell death is proven by 
preventing death via specific inhibition of the causative pathway
134
. Alike apoptosis, necrosis 
can be a programmed form of cell death, referred to regulated cell necrosis
96
.  Based on the 
molecular mechanisms involved, these regulated necrosis pathways are named as RIPK-
mediated necroptosis, iron-mediated ferroptosis, PARP-mediated parthanatos, mitochondrial 
permeability transition-related regulated necrosis, caspase-1/11-mediated pyroptosis etc
134
. 
However, it remained unclear if NETosis is at all a unique cell death category also because 
none of the other cell death categories is cell type-specific. In contrast, NETosis is mode of 
cell death distinguished just based on morphological appearance. Moreover, as none of the 
aforementioned signaling elements is specific for neutrophils, the underlying route of 
“NETosis” remained elusive.  In addition, NET release has been reported in cells other than 
neutrophils, referred to as “ETosis”
58
. We were interested in dissecting the exact mode of cell 
death beyond the morphological appearance of ‘NET structures’ upon crystal stimulations. Is 
NETosis a unique mode of cell death? Are these NET-like structures consequence of mere 
another known regulated necrosis pathways that involve plasma membrane rupture?  
Since we were interested in the pathophysiological mechanisms of gout, we focused 
on MSU crystals induced neutrophil cell death. We observed that only chemical inhibitors of 
the necroptosis pathway such as RIPK1 stabilizers necrostatin (Nec)-1 and Nec-1s or the 
MLKL inhibitor NSA inhibited NET release and neutrophil necrosis upon 2 hours of PMA or 
MSU crystals stimulation of human neutrophils
142
. These stimuli also increased the 
expression of RIPK3 and pMLKL, two core proteins of necroptosis signaling, in a time-
dependent manner, suggesting the involvement of the necroptosis signaling pathway in PMA- 
and MSU crystal-induced NET release
142
 (figure 40). 
These findings were corroborated by similar observations in Ripk3-deficient murine 
neutrophils. Furthermore, Nec-1 or NSA did not affect MSU crystals- or PMA-induced ROS 
production in neutrophils and neutrophils of patients with chronic granulomatous disease 
(non-functional NADPH oxidase) did not express pMLKL after PMA stimulation
142
 , 
suggesting that pMLKL is a downstream event to ROS. Obviously, PMA and MSU crystals 
trigger NET-like chromatin release in the context of neutrophil necroptosis. Recently, Schauer 
et. al. demonstrated that MSU crystals can induce aggregates of NETs, and the tophi, 
pathognomonic structures of chronic gout, share characteristics of aggregated NETs
37
.   
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Figure 40: Chromatin release as a consequence of neutrophil necroptosis. Stimuli like MS) crystals and 
PMA induce activation of a receptor interacting protein kinase (RIPK)3- and mixed lineage kinase domain-like 
(MLKL)-dependent signaling pathway downstream of ROS. This leads to plasma membrane rupture and NET-
like chromatin release together with granular enzymes as a consequence at around 2 hours of stimulation. 
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We observed that the deficiency of Ripk3, as well as inhibitors of the necroptosis pathway, 
inhibited MSU crystal-induced NET formation and gout-like tophus formation in vivo
142
, 
confirming the involvement of neutrophil necroptosis along NET release (figure 40).  
Unlike RIPK3/MLKL-mediated neutrophil necroptosis
143
, the rapid NET formation 
without cell death does not involve perforation of the plasma membrane
66
. Accordingly, the 
independency of RIPK3/MLKL pathway for this rapid NET formation (45 min after 
neutrophil stimulation) was also recently demonstrated by Amini et. al. using  stimuli like E. 
coli, GM-CSF-primed LPS or complement factor C5a 
144
. On first view, these observations 
seem contradictory to the involvement of necroptosis in PMA- and MSU crystal-induced NET 
release during neutrophil necrosis
143
. But obviously the nature of NET formation can differ in 
terms of timing, type of stimuli or context of disease. The term ‘NETosis’ is inappropriate not 
only to describe a vital process but also when NET release comes as a passive process 
secondary to plasma membrane rupture of neutrophils undergoing necroptosis or even other 
forms of regulated cell death. On the other hand NET formation from neutrophils that remain 
vital is a primary event and a particular feature of host defense unique to neutrophils. In 
addition, it becomes important to carefully design future studies related to NETs and carefully 
distinguish the process of NET formation from that of neutrophil cell death.  
In an independent study, we investigated crystal induced cell death mechanisms in 
different non-immune cell types
37
. Crystals in the micrometer range of calcium oxalate, 
calcium pyrophosphate, cystine or monosodium urate induce direct cell necrosis in a variety 
of different epithelial and mesenchymal cell types 
145
. Crystal-induced cell death involve 
RIPK-3 and MLKL hence, crystals kill cells via a regulated form of necrosis classified as 
necroptosis (Figure 41) 
146
. This finding could be validated in vivo as Ripk3- or Mlkl-deficient 
mice are protected from calcium oxalate crystal-induced tubular necrosis as acute kidney 
injury
147
. RIPK1 is an upstream inhibitor of necroptosis and small molecule modulators of 
RIPK1, the necrostatins, enhance this inhibitory effect and can suppress crystal-induced 
necroptosis
145,148
.  
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Figure 41: Schematic illustration of crystal-induced necroptosis and inflammation (necroinflammation). 
During crystallophathies, crystals are formed and deposited inside the organ, for example, kidney stone disease 
or joint, for example, gouty arthritis. On crystallization, crystals are phagocytized by parenchymal cells where 
they activate the RIPK1, RIPK3 and MLKL pathway of necroptosis, a prototype form of regulated necrosis, by 
inducing a series of phosphorylation events.  
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How exactly crystals trigger RIPK1 activation in both immune and non-immune cells 
remains uncertain. It was shown that MSU crystals can switch on the Syk signalling in 
dendritic cells via binding to lipid rafts
149
. Crystals activate the NLRP3 inflammasome via 
lysosomal leakage of cathepsins into the cytosol
150
. Cathepsin B was reported to inhibit 
necroptosis by cleaving RIPK1
151
. This could also be a possibility of upstream events that 
lead to crystal-induced necroptosis. Our data also suggest that crystal-induced cytotoxicity 
might not involve TNFsince TNFblocker etanercept did not block necroptosis in-vitro. 
However, it is certain that secondary TNF-driven necroptosis further contributes to 
cytotoxicity in in-vivo conditions (figure 41). Consequently, the therapeutic blockade of this 
pathway, for example, with the soluble TNFR2-IgG fusion protein or the RIPK1 stabilisator 
necrostatin-1 prevented crystal-induced tissue necrosis and organ dysfunction
152
. These data 
indicate that crystal-induced necroptosis can be one of the initial responses upon onset of 
various crystallopathies.  
Apart from cytotoxic effects, crystals can directly activate immune system and 
promote inflammation. Martinon & Tschopp showed that MSU and CPPD crystals activate 
macrophages for caspase-1-dependent release of mature IL-1β by activating the NLRP3 
inflammasome
6
. Subsequently, this finding was confirmed in large range of crystals and 
microparticles
153
. These include crystals or particulates of cholesterol 
154
, calcium oxalate 
155
, 
calcium phosphate 
156
, calcium pyrophosphate 
157
, cystine 
158
, silica 
159,160
, asbestos 
160
,  
cigarette smoke-related microparticles 
161
, and nanoparticles, e.g. formed by titanium dioxide 
162,163
, carbon 
164
, polysterene 
165
,. Whether crystal cytotoxicity is a consequence of NLRP3 
activation or an inflammasome-independent event with distinct signalling pathways are the 
important questions. Crystal-induced NLRP3 activation could imply NLRP3-caspase-1/11-
mediated pyroptosis as a mode of crystal-induced regulated cell death, as it has been 
described to occur in infected macrophages
166
 
107
 
167
. However, we excluded this option since 
caspase blockade did not affect crystal cytotoxicity of neutrophils as well as other non-
immune cells. Moreover, caspase blockade also excluded apoptosis as another form of 
regulated cell death.  
Together with direct interaction with immune system, crystals also trigger 
inflammation by killing cells because necrotic cells release numerous proinflammatory 
elements such as cytokines like IL1-ß, IL-6, TNFproinflammatory alarmins, proteases, and 
DAMPs that have the capacity to activate Toll-like receptors (e.g. HMGB1, histones, 
mitochondrial DNA, demethylated DNA/RNA, etc.) or inflammasomes (e.g. ATP, histones, 
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uric acid, dsDNA, etc.) 
168,169
 (Figure 42). Activation of these receptors ultimately leads to the 
release of proinflammatory cytokines, kinins, and lipid mediators that install a local 
inflammatory response, i.e. vasodilation endothelial dysfunction with increased vascular 
permeability (swelling) and leukocyte infiltration. Crystal induced neutrophil necroptosis lead 
to release of chromatin made up of histones and DNA. Histones are known to have direct 
cytotoxic affects and can further act as DAMPs. Also local complement activation can be 
involved
170,171
. Thus, crystal induced necroptosis of immune cells (neutrophils) and non-
immune cells leads to an inflammatory response and pro-inflammatory cytokines like 
TNFcan also further activate the RIPK1, RIPK3 and MLKL pathway of necroptosis via 
TNFR1 in neighbouring cells. This auto-amplification loop between cell death and 
inflammation is known as necroinflammation (figure 42).  
Necroinflammation eventually leads to aggravation of tissue injury, and if remain 
uncontrolled then to organ failure
51
. Thus, blocking necroptosis during the early stage of 
tissue injury may help to prevent subsequent auto-amplification loop of inflammation, 
immune-mediated pathology and organ failure.  Thus, Necroinflammation contribute to the 
typical clinical presentations of acute crystallopathies such as gouty arthritis 
3
.  
However, there are some limitations to the conclusions drawn from the present study. 
1. Most of the conclusions of the study are based on in vitro observation. Activity of 
neutrophils in physiological condition is highly influenced by surrounding environment 
and presence of various factors.  
2. Neutrophils are highly sensitive cells and can be activated by mere errors in physical 
handling. This leads to different observations in different settings (different laboratories).  
3. One of the limitations of the study is methods that are used to study neutrophil NETs and 
cell death. We have combined approaches from cell death fields to use chemical inhibitors 
of cell death mechanisms and approaches of imaging to study the morphology of NETs. 
However, various imaging approach cannot distinguish between NETs and cell death. 
Whether chromatin release is a secondary event to neutrophil necroptosis after plasma 
membrane rupture or it involves another specific biochemical pathway cannot be fully be 
answered with present approach.  
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Figure 42:  Schematic representation of necroinflammation.  The regulated necrosis in immune and non-
immune cells like necroptosis or NETs lead to the release of various DAMPs like mitochondrial protein, 
chromatin or cytosolic proteins. These DAMPs can induce strong inflammatory responses by activating 
inflammatory signaling pathways like inflammosomes or NET formation. Furthermore, these inflammatory 
responses lead to induction of more DAMPs, inducing the vicious cycle of necroinflammation. 
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4. The source of neutrophils may affect the NET formation process in case of mouse 
neutrophils. Different stimuli may also lead to NET formation without involving cell 
death. Amini et. al showed ‘vital NETs’ in mouse neutrophils derived from Ripk3-
deficient mice upon stimulations with E. coli, GM-CSF-primed LPS or complement factor 
C5a but not with crystals 
144
. This look contradictory to our observation. However, the 
source of neutrophils was different in both the studies. Amini et. al showed rapid NETs in 
bone-marrow derived mouse neutrophils whereas our study used peripheral blood 
neutrophils. More detail studies are thus needed to understand NET formation procedures 
and their interaction with neutrophil cell death. 
5. To study and image NETs in in vivo models is extremely difficult. Imaging NETs and cell 
death in vivo may help understand neutrophil necroptosis in a better manner.  
6. Whether the variety of the involved forms of regulated cell death depend on the crystal 
type, crystal size or the affected cell type remains to be further characterized in detail. 
 
In conclusion, crystals are potent inducers of necroptosis in immune and non-immune 
cells, and NET-like chromatin release is a consequence or a secondary event following 
necroptotic neutrophil death. These findings imply TNFR1, RIPK1, RIPK3 and MLKL being 
potential therapeutic targets to limit tissue injury in crystallopathies i.e. gouty arthritis.  
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 7. Abbrevations 
A 
ACPAs anticitrullinated peptide antibodies  
ANAs antibodies against histones 
ANCAs anti-neutrophil cytoplasmic antibodies 
C 
CGD chronic granulomatous disease 
COPD chronic obstructive pulmonary disease 
CPP calcium pyrophosphate dihydrate  
CYPD cyclophilin D 
D 
DAMPs danger associated molecular patterns  
DC dendritic cells 
E 
ELISA enzyme-linked immunosorbent assay  
G 
GAS group A Streptococcus 
G-CSF Granulocyte-colony stimulating factor 
GPX4 glutathione peroxidase 4 
H 
HIV-1 human immunodeficiency virus 1  
I 
IF immunofluorescence  
IFN-α interferon α 
IL interleukin 
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N 
NADPH 
Nicotinamide adenine dinucleotide 
phosphate 
NET Neutrophil extracellular trap 
NE neutrophil elastase  
P 
PAD4 peptidyl-arginine deiminase 4  
PARP1 poly ADP-ribose plymerase 1 
PMA phorbol 12-myristate 13-acetate  
PMN polymorphonuclear leukocytes  
PRR pattern recognition receptors  
PSGL1 P-selectin glycoprotein ligand 1 
R 
RA  Rheumatoid arthritis 
RCD regulated cell death 
RIPK receptor-interacting protein kinase  
RN regulated necrosis 
RNP ribonucleoproteins 
L 
LPS lipopolysaccharide 
M 
MCP-1 monocyte chemoattractant protein  
MLKL mixed lineage kinase domain-like  
MOMP mitochondrial outer membrane permeabilization  
MPO myeloperoxidase 
MPT Mitochondrial permeability transition 
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ROS reactive oxygen species 
S 
SEM scanning electron microscopy 
SF synovial fluids  
SLE Systemic lupus erythematosus  
SOCS suppressors of cytokine signaling  
STATs 
signal transducers and activators of 
transcription 
T 
TGF transforming growth factor  
TLR toll-like receptor  
TNF Tumour necrosis factor  
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8. Appendix 
Composition of buffers used 
FACS buffer :  
Sterile DPBS    500 ml  
Na Azide    500 mg (0.1 % )  
BSA     1 g (0.2 %)  
 
10X HBSS (Hank’s Balanced Saline Solution) with Ca, Mg:  
For 1000 ml  
KCl     4 g  
KH
2
PO
4    
0.6 g  
NaCl     80 g  
Na
2
HPO
4
.2H
2
O   0.621 g  
NaHCO
3    
3.5 g  
CaCl
2     
1.4 g (or CaCl
2
.2H
2
O 1.854 g)  
MgCl
2
.6H
2
O   1 g  
MgSO
4
.7H
2
O    1 g  
D-Glucose    10 g  
Dissolve in 900 ml of distilled water and adjust to pH 7.4 with 1N HCl or 1N NaOH. 
Make up the volume with distilled water to 1000 ml.  
 
10X HBSS (Hank’s Balanced Saline Solution) without Ca, Mg:  
For 1000 ml  
KCl     4 g  
KH2PO4    0.6 g 
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NaCl     80 g  
Na
2
HPO
4
.2H
2
O   0.621 g  
Dissolve in 1000 ml and autoclave.  
 
50 % Glycerol in 20 mM Tris-HCl (pH 7.5), 1 mM MgCl
2
:  
a. 0.48 g of Tris-HCl in 100 ml of distilled water, adjust pH to 7.4 (= 40 mM)  
b. 50 ml of Glycerol 100 % + 50 ml of 40 mM Tris-HCl (20 mM)  
c. Add 100 ul of 1M MgCl
2 
solution.  
 
EDTA 2 mM: 
EDTA 7.44 mg in 10 ml HBSS (without Ca, Mg) 
To be preheated in 37 0C water bath before use. 
 
Citrate buffer 10X: 
110 mM Sodiumcitrate in ddH2O 
with 2N NaOH to pH 6 
 
PBS: 
2.74 M NaCl 
54 mM KCl 
30 mM KH2PO4 
130 mM Na2HPO4 
in ddH2O 
Adjust pH to 7.5 with HCl 
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Gel Running Buffer (10x): 
  Tris        30g 
  Glycine    144g 
  SDS          5g 
 Make up volume to 1000ml (pH 8.3) 
 
Transfer Buffer (1x): 
  Tris         1.5g 
  Glycine  7.2g 
 Make up volume to 500ml  
 
TBS (10x): 
  Tris        24.23g 
  NaCl       80.06g 
  Conc. HCL around 17.5ml 
 Make up volume to 1000ml (pH 7.6) 
 
TBS-T (1x): 
  TBS (1x)      1000ml 
  Tween 20     1ml 
 
Sample buffer: 
  Milipore water   3,8 ml 
0,5 M Tris HCl, pH 6,8  1 ml 
Glycerol   0,8 ml 
10% SDS   1,6 ml 
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2- mercaptoehanol  0,4 ml 
1% (w/v) bromophenol blue  0,4 ml 
  Total  8 ml 
 
Separating Buffer (1x): 
  Tris (1.5mM)         18,2g 
  SDS             400mg 
 Make up volume to 100ml (pH 8.8) 
 
Stacking Buffer (1x): 
  Tris (0.5mM)       6,05g 
  SDS             400mg 
 Make up volume to 100ml (pH 6.8) 
 
Staining solution: 
  Methanol   500ml 
  Acetic acid    100ml 
  Water    400ml 
 Coomasie Brilliant blue R : 2.5 g  (0.25%) 
 
Destaining solution: 
  Methanol   150ml 
  Acetic acid    100ml 
  Water    750ml 
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